<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nanobiomedicine (Rij)</journal-id><journal-id journal-id-type="iso-abbrev">Nanobiomedicine (Rij)</journal-id><journal-id journal-id-type="publisher-id">NAB</journal-id><journal-id journal-id-type="hwp">spnab</journal-id><journal-title-group><journal-title>Nanobiomedicine</journal-title></journal-title-group><issn pub-type="epub">1849-5435</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6029241</article-id><article-id pub-id-type="doi">10.5772/58841</article-id><article-id pub-id-type="publisher-id">10.5772_58841</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Engineering Iron Oxide Nanoparticles for Clinical Settings </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cortajarena</surname><given-names>Aitziber L.</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff2-58841">2</xref><xref ref-type="other" rid="equal1-58841">ζ</xref></contrib><contrib contrib-type="author"><name><surname>Ortega</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff2-58841">2</xref><xref ref-type="aff" rid="aff3-58841">3</xref><xref ref-type="other" rid="equal1-58841">ζ</xref></contrib><contrib contrib-type="author"><name><surname>Ocampo</surname><given-names>Sandra M.</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="other" rid="equal1-58841">ζ</xref></contrib><contrib contrib-type="author"><name><surname>Gonzalez-García</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref></contrib><contrib contrib-type="author"><name><surname>Couleaud</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff2-58841">2</xref></contrib><contrib contrib-type="author"><name><surname>Miranda</surname><given-names>Rodolfo</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref></contrib><contrib contrib-type="author"><name><surname>Belda-Iniesta</surname><given-names>Cristobal</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff4-58841">4</xref><xref ref-type="aff" rid="aff5-58841">5</xref></contrib><contrib contrib-type="author"><name><surname>Ayuso-Sacido</surname><given-names>Angel</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff4-58841">4</xref><xref ref-type="corresp" rid="corresp1-58841">*</xref></contrib></contrib-group><aff id="aff1-58841"><label>1</label> Instituto Madrileño de Estudios Avanzados IMDEA-Nanociencia, Madrid, Spain</aff><aff id="aff2-58841"><label>2</label> Centro Nacional de Biotecnología (CNB-CSIC) - IMDEA Nanociencia Associated Unit “Unidad de Nanobiotecnología”, Cantoblanco, Madrid, Spain</aff><aff id="aff3-58841"><label>3</label> Institute of Biomedical Engineering, University College London, UK</aff><aff id="aff4-58841"><label>4</label> Centro Integral Oncológico Clara Campal (CIOCC) and Instituto de Medicina Molecular Aplicada (IMMA). Hospital de Madrid Foundation, Madrid, Spain</aff><aff id="aff5-58841"><label>5</label> National School of Health, ISCIII, Madrid, Spain</aff><author-notes><corresp id="corresp1-58841"><label>*</label> Corresponding author E-mail: <email xlink:href="ayusosacido@fundacionhm.com">ayusosacido@fundacionhm.com</email></corresp><fn fn-type="equal" id="equal1-58841"><label>ζ</label><p><text><SENT sid="1" pm="."><plain>Equal contribution </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>1</day><month>1</month><year>2014</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2014</year></pub-date><volume>1</volume><elocation-id>2</elocation-id><history><date date-type="received"><day>22</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>1</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 The Author(s). Licensee InTech.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Iron oxide nanoparticles (IONPs) occupy a privileged position among magnetic nanomaterials with potential applications in medicine and biology. </plain></SENT>
<SENT sid="3" pm="."><plain>They have been widely used in preclinical experiments for imaging contrast enhancement, magnetic resonance, immunoassays, cell tracking, tissue repair, magnetic hyperthermia and drug delivery. </plain></SENT>
<SENT sid="4" pm="."><plain>Despite these promising results, their successful translation into a clinical setting is strongly dependent upon their physicochemical properties, toxicity and functionalization possibilities. </plain></SENT>
<SENT sid="5" pm="."><plain>Currently, IONPs-based medical applications are limited to the use of non-functionalized IONPs smaller than 100 nm, with overall narrow particle size distribution, so that the particles have uniform physical and chemical properties. </plain></SENT>
<SENT sid="6" pm="."><plain>However, the main entry of IONPs into the scene of medical application will surely arise from their functionalization possibilities that will provide them with the capacity to target specific cells within the body, and hence to play a role in the development of specific therapies. </plain></SENT>
<SENT sid="7" pm="."><plain>In this review, we offer an overview of their basic physicochemical design parameters, giving an account of the progress made in their functionalization and current clinical applications. </plain></SENT>
<SENT sid="8" pm="."><plain>We place special emphasis on past and present clinical trials. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>Iron Oxide Nanoparticles</kwd><kwd>IONP</kwd><kwd>SPION</kwd><kwd>USPION</kwd><kwd>VSPION</kwd><kwd>Drug Delivery</kwd><kwd>Magnetic Hyperthermia</kwd><kwd>MRI</kwd><kwd>Nanomedicine</kwd></kwd-group></SecTag><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="section1-58841"><title><text><SENT sid="9" pm="."><plain>1. </plain></SENT>
<SENT sid="10" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="11" pm="."><plain>Over the last decade, nanotechnology has become more relevant in many industrial sectors, including medicine. </plain></SENT>
<SENT sid="12" pm="."><plain>In general, the future projection and promotion of iron oxide nanoparticles (IONPs) as a point of reference among other magnetic nanomaterials for clinical applications relies chiefly on their biocompatibility in moderate doses, their relatively well-known iron metabolic pathways and their ability to be produced in a wide range of sizes and shapes with biofunctionalization potential. </plain></SENT>
<SENT sid="13" pm="."><plain>Additionally, the added advantage of magnetic actuation makes IONPs stand out from many other nanotechnology-based therapeutic and diagnostic approaches. </plain></SENT>
<SENT sid="14" pm="."><plain>In any case, IONPs have already passed through the preclinical stage to become a reality in clinical practice. </plain></SENT>
<SENT sid="15" pm="."><plain>In particular, they improve imaging-based diagnostics of immunological diseases, cardiovascular and cerebrovascular pathologies and cancer. </plain></SENT>
<SENT sid="16" pm="."><plain>They show great promise to serve as a cell tracking system in cell-based therapies, and to generate local temperature increases in the magnetic thermotherapy of solid tumours. </plain></SENT>
</text></p><p><text><SENT sid="17" pm="."><plain>The purpose of this work is to review the basic parameters involved in the design of IONPs and their functionalization possibilities which, in the next few years, will bring into being a completely new generation of IONPs with selective targeting properties. </plain></SENT>
<SENT sid="18" pm="."><plain>Functionalized and multifunctionalized IONPs will become nanocarriers that will improve the selectivity of specific cells and, therefore, allow for the development of specific therapies. </plain></SENT>
<SENT sid="19" pm="."><plain>We describe their biochemical features, their cell internalization and in vivo administration, as well as the reduced toxicology effects that have contributed to their successful use in current clinical applications. </plain></SENT>
<SENT sid="20" pm="."><plain>Additionally, we discuss most of the past and present clinical trials involving IONPs, placing special emphasis on their interactions with different compartments of the immune system. </plain></SENT>
<SENT sid="21" pm="."><plain>Finally, we highlight the potential advances in functionalization and magnetic hyperthermia as two fields that will surely push forward the clinical use of IONPs. </plain></SENT>
</text></p></sec></SecTag><sec id="section2-58841"><title><text><SENT sid="22" pm="."><plain>2. </plain></SENT>
<SENT sid="23" pm="."><plain>Basic physicochemical characteristics of IONPs </plain></SENT>
</text></title><sec id="section3-58841"><title><text><SENT sid="24" pm="."><plain>2.1 Size </plain></SENT>
</text></title><p><text><SENT sid="25" pm="."><plain>This is arguably the most important parameter upon which any IONPs system must be designed. </plain></SENT>
<SENT sid="26" pm="."><plain>First, it profoundly affects the dynamics of the magnetic moments in magnetic NPs—also regarded as the magnetic relaxation processes—that also depend on other parameters, such as temperature or externally applied magnetic fields. </plain></SENT>
<SENT sid="27" pm="."><plain>Second, particle size is of paramount importance in the detection, internalization and eventual fate of IONPs inside mammalians. </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>Two of the most relevant magnetic scale lengths that characterize magnetic NP systems are the superparamagnetic radius (RSPM) and the single domain radius (RSD). RSPM refers to the maximum particle size up to which a superparamagnetic regime is observed. RSD indicates the value below which the formation of magnetic domains—regions grouping magnetic moments with the same orientation—is no longer energetically favourable and indicates that the most stable magnetic configuration for the particle is the single domain state [1]. </plain></SENT>
<SENT sid="29" pm="."><plain>Both RSD and RSPM can be worked out from the anisotropy constant (K), the dimensionless hardness parameter (κ) and the exchange stiffness constant (A) [2] of the material of interest. Table 1 summarizes these parameters for maghaemite and magnetite, the most commonly used iron oxides in biomedicine, and gives a glimpse of the range of magnetic behaviours of IONPs with varying particle size. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="table1-58841" orientation="portrait" position="float"><label>Table 1.</label><caption><p><text><SENT sid="30" pm="."><plain>Characteristic magnetic length scales for the most relevant iron oxides [123][124][125]. </plain></SENT>
<SENT sid="31" pm="."><plain>Data for iron are included for comparison. </plain></SENT>
</text></p></caption><alternatives><graphic xlink:href="10.5772_58841-table1"/><table frame="border" rules="all" width="100%"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="1" colspan="1"><text><SENT sid="32" pm="."><plain>K </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="33" pm="."><plain>A </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="34" pm="."><plain>MS </plain></SENT>
</text></th><th align="center" rowspan="2" colspan="1"><text><SENT sid="35" pm="."><plain>k </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="36" pm="."><plain>lex </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="37" pm="."><plain>Rsd </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="38" pm="."><plain>Rspm </plain></SENT>
</text></th></tr><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="39" pm="."><plain>(J/m3) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="40" pm="."><plain>(J/m) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="41" pm="."><plain>(A/m) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="42" pm="."><plain>(nm) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="43" pm="."><plain>(nm) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="44" pm="."><plain>(nm) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="45" pm="."><plain>Maghemite </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="46" pm="."><plain>4.6×103 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="47" pm="."><plain>∼10−11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="48" pm="."><plain>3.8×105 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain>0.16 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>7.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>42.5 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>17.5 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>Magnetite </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>1.35×104 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain>133×10−11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>4.8×105 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>0.21 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>6.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>52.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>12.2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>Iron </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>4.8×104 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>1.49×10−11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>1.71×106 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>0.11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>2.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>8.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>8.0 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><p><text><SENT sid="69" pm="."><plain>IONPs may be produced by a number of methods that allow for precise control over their size, shape and surface chemistry [3][4][5][6]. </plain></SENT>
<SENT sid="70" pm="."><plain>These parameters, along with others, can be used to classify IONPs for different purposes [7]. </plain></SENT>
<SENT sid="71" pm="."><plain>With reference to particle size, the researchers working on IONPs in medicine and biology—especially in the MRI community—use an informal classification divided into distinct ranges as follows: below 10 nm, very small superparamagnetic iron oxide NPs (VSPIONs); between 10 and 50 nm, ultrasmall superparamagnetic iron oxide NPs (USPIONs); and between 50 and 180 nm, superparamagnetic iron oxide NPs (SPIONs). </plain></SENT>
</text></p><p><text><SENT sid="72" pm="."><plain>Although this classification might be useful only for the purpose of gathering some size ranges showing similar circulation and relaxational properties for specific applications, IONPs are persistently referred to in the literature as SPIONs, regardless of their true magnetic properties. </plain></SENT>
<SENT sid="73" pm="."><plain>This misuse of the term SPION is both inaccurate and confusing, as the lower-end value of the SPIONs' size range lies at the theoretical transition between superparamagnetic and single domain states for iron oxides (Table 1). </plain></SENT>
<SENT sid="74" pm="."><plain>Thus, most of the particle sizes encompassed within this range would in fact be single domain, not superparamagnetic. </plain></SENT>
<SENT sid="75" pm="."><plain>Interparticle interactions and surface effects further complicate this picture by shifting RSPM away from its theoretical value. </plain></SENT>
<SENT sid="76" pm="."><plain>Therefore, we recommend avoiding, where possible, the SPION-based nomenclature and using a more general one describing the actual behaviour of the IONPs experimentally characterized by magnetic measurements, either: (i) based on size effects (superparamagnetic, single domain and multidomain) or (ii) on the coupling between magnetic moments (ferro-, ferri-, or antiferromagnetic, as applicable). </plain></SENT>
<SENT sid="77" pm="."><plain>Another source of confusion is the conflation of the numerical size values measured by different techniques, more specifically the “physical” size—typically obtained through electron microscopy, X-ray diffractometry, or similar means—and the hydrodynamic size—measured by dynamic light scattering or acoustic spectroscopy, and a value that, besides the physical particle size, also takes into account the thickness of any coating agent and the solvation molecules from the solvent. </plain></SENT>
<SENT sid="78" pm="."><plain>A final word of caution in this regard is that many IONPs are prepared by forming aggregates of variable size instead of a dispersion of single NPs; the size of the aggregates—often referred to as multi-cores—and that of the single particles are sometimes carelessly conflated. </plain></SENT>
</text></p><p><text><SENT sid="79" pm="."><plain>From a biological point of view, IONPs can travel anywhere through the circulatory system of the human body, since the smallest capillaries are 4–6 μm wide [8]. </plain></SENT>
<SENT sid="80" pm="."><plain>IONPs under 100 nm are considered to be suitable for any application requiring tissue penetration, but those around 5 nm are more effective for tumour penetration [9]. </plain></SENT>
<SENT sid="81" pm="."><plain>Nonetheless, at the cellular level, NP size also influences the binding affinity of molecules, the uptake of additional particles into the cell, and the actual location within the cell. </plain></SENT>
<SENT sid="82" pm="."><plain>For a given NP shape, there is an optimal size for NP diffusion through the potential barrier characterizing the particle–cell interaction, as found by theoretical models [10][11]. </plain></SENT>
<SENT sid="83" pm="."><plain>Numerical calculations of these models indicate that the optimal NP size for a reasonably quick endocytosis is somewhere around 25 to 35 nm. </plain></SENT>
<SENT sid="84" pm="."><plain>Regardless of the particular considerations in each of the proposed models, the aforementioned optimum size range is given by the interplay between the kinetics and thermodynamics of the diffusion–absorption process of NPs relative to the thermal energy involved. </plain></SENT>
<SENT sid="85" pm="."><plain>Of particular note is that within the framework of the model proposed by Shi et al., the optimum particle sizes obtained do not depend on the absorption coefficient, the viscosity of the medium, or the cell size [10] (Figure 1). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig1-58841" orientation="portrait" position="float"><label>Figure 1.</label><caption><p><text><SENT sid="86" pm="."><plain>Membrane deformation for (a) shallow wrapping and (b) deep wrapping of a cubic-shaped nanoparticle. </plain></SENT>
<SENT sid="87" pm="."><plain>The network of edges and triangles describes the membrane shape and has been used for the numerical calculation of the curvature energy. </plain></SENT>
<SENT sid="88" pm="."><plain>[Adapted with permission from S. Dasgupta, et al., Nano Letters 14(2) (2014) 687–693. </plain></SENT>
<SENT sid="90" pm="."><plain>Copyright 2014 American Chemical Society]. </plain></SENT>
<SENT sid="91" pm="."><plain>(c) Values of diffusion length (ldiff) of nanoparticles as a function of particle size (R) at fixed values of aspect ratio (a) [Reprinted with permission from X. Li, Journal of Applied Physics, vol. </plain></SENT>
<SENT sid="93" pm="."><plain>111 (2012) 024702. </plain></SENT>
<SENT sid="94" pm="."><plain>Copyright 2012, AIP Publishing LLC]. </plain></SENT>
<SENT sid="95" pm="."><plain>(d) Normalized absorption rate of cylindrical particles with different diameters and aspect ratios [Permission pending]. </plain></SENT>
</text></p></caption><graphic xlink:href="10.5772_58841-fig1"/></fig></SecTag></sec><sec id="section4-58841"><title><text><SENT sid="96" pm="."><plain>2.2 Shape </plain></SENT>
</text></title><p><text><SENT sid="97" pm="."><plain>Consider a magnetic particle as composed of many positive and negative poles; these will cancel each other, but there will still be free poles at the surface of the particle. </plain></SENT>
<SENT sid="98" pm="."><plain>These free poles create a magnetic field—the demagnetizing field (Hd)—that depends on the particle shape and is opposed to the direction of the external field (Hext). </plain></SENT>
<SENT sid="99" pm="."><plain>It follows that the effective magnetic field (Heff) acting on a particle will be different from Hext:Heff = Hext -Hd, where Hd = N·M, with M the magnetization of the particle and N the so-called demagnetizing factor (N). </plain></SENT>
<SENT sid="100" pm="."><plain>In the case of a spherical shape, N = 1 due to the even distribution of free poles over the particle's surface. </plain></SENT>
<SENT sid="101" pm="."><plain>Other morphologies different from a perfect sphere—the usual case in many real systems—may be approximated to distorted ellipsoids. </plain></SENT>
<SENT sid="102" pm="."><plain>In this way, the anisotropy energy associated with the shape of an ellipsoidal particle with its major axis lying along the z direction equals [12]: Eshape = [μ0MS2(Nx-Nz)/2]−1, where MS is the saturation magnetization and μ0 is the permeability of the free space. </plain></SENT>
</text></p><p><text><SENT sid="103" pm="."><plain>Besides its contribution to the total anisotropy energy of magnetic particles, the role of the particle shape in the magnetic properties of NPs is linked to the stability of the single domain configuration. </plain></SENT>
<SENT sid="104" pm="."><plain>For example, disc-like NPs with relatively higher aspect ratios may show a closed spiral arrangement of their magnetic moments [13], called a vortex state, whereas particles with the same shape but lower aspect ratios show the typical parallel arrangement of moments commonly seen in uniformly magnetized single domain NPs [14]. </plain></SENT>
</text></p><p><text><SENT sid="105" pm="."><plain>On the biological side, the shape of an NP determines the extent to which the NP will interact with membrane receptors and hence the degree of internalization. </plain></SENT>
<SENT sid="106" pm="."><plain>Shi et al. modelled the particle–cell interaction by considering the diffusion and absorption of rod-like (cylindrical) and spherical NPs through a partially absorbing spherical cell [15]. </plain></SENT>
<SENT sid="107" pm="."><plain>For a fixed set of physical parameters of the particles, cell and medium, numerical results show that for each NP size there is a specific aspect ratio value for which the absorption rate is maximum (red region in Figure 2A), demonstrating the joint relevance of the size and shape of NPs to their internalization. </plain></SENT>
<SENT sid="108" pm="."><plain>Strange as it may seem, the outcomes of this work also suggest that the optimum particle size and shape for endocytosis do not depend noticeably on either the particular NP's absorption mechanism or the viscosity of the medium. </plain></SENT>
<SENT sid="109" pm="."><plain>Subsequent models based on similar grounds coincide in more general aspects. </plain></SENT>
<SENT sid="110" pm="."><plain>Noticeably, in particles with increasing aspect ratios, endocytosis becomes energetically favourable with decreasing particle sizes (Figure 2B). </plain></SENT>
<SENT sid="111" pm="."><plain>Particle orientation adds to the intricate influence of particle shape. </plain></SENT>
<SENT sid="112" pm="."><plain>Recent theoretical calculations based on membrane mechanics show how possible particle wrapping states—designated as shallow (Figure 2C) and deep (Figure 2D)—evolve, depending on the particle aspect ratio and edge curvature [16]. </plain></SENT>
<SENT sid="113" pm="."><plain>The proposed model predicts that particles with a high aspect ratio and round tips enter the cell membrane with their long edge parallel to the membrane, whereas those with low aspect ratio and sharp edges proceed tip-first. </plain></SENT>
<SENT sid="114" pm="."><plain>Despite its intrinsic limitations, this model provides the basis for making predictions of particle toxicity considering particles' shape and wrapping degree. </plain></SENT>
<SENT sid="115" pm="."><plain>Other studies on the interaction between other types of nanostructures, like nanosheets or nanotubes, and cell membranes have been reviewed elsewhere [17]. </plain></SENT>
<SENT sid="116" pm="."><plain>Although some of the results reported for these nanostructures sharply differ from those for NPs, many others are consonant; for instance, some aspects relating to the uptake mechanism of nanotubes and elongated NPs with variable edge curvature [17][18]. </plain></SENT>
<SENT sid="117" pm="."><plain>Finally, the circulation and the eventual in vivo fate of IONPs inside the body are also determined by particle shape to a great extent [19]. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig2-58841" orientation="portrait" position="float"><label>Figure 2.</label><caption><p><text><SENT sid="118" pm="."><plain>Schematic representation of the theoretical magnetic regimes (superparamagnetic, single domain, multidomain) expected for both magnetite and maghaemite, along with some relevant applications as a function of the particle size. </plain></SENT>
<SENT sid="119" pm="."><plain>(*) Magnetofection is a trademark of Christian Bergemann and Dr Christian Plank. </plain></SENT>
<SENT sid="120" pm="."><plain>(**) Refers to uncoated, single nanoparticles. </plain></SENT>
<SENT sid="121" pm="."><plain>The size ranges represented are approximate and comprise the most common cases. </plain></SENT>
</text></p></caption><graphic xlink:href="10.5772_58841-fig2"/></fig></SecTag></sec><sec id="section5-58841"><title><text><SENT sid="122" pm="."><plain>2.3 Surface charge density </plain></SENT>
</text></title><p><text><SENT sid="123" pm="."><plain>An additional degree of complexity linked to the biological activity of NPs is constituted by their effective superficial charge, which determines the type of active or passive functionalization through specific molecules and the relevant particle–cell interaction mechanisms, which is revisited in the following sections. </plain></SENT>
<SENT sid="124" pm="."><plain>In this regard, the magnetic properties of NPs would remain virtually unaffected by their surface charge, even though the coating used to tune the surface charge or the affinity for a particular target may introduce sizeable modifications, as discussed later. </plain></SENT>
<SENT sid="125" pm="."><plain>As a first approximation, bare IONPs possess a surface charge strongly influenced by the environment, involving the pH and the ionic strength of the medium. </plain></SENT>
<SENT sid="126" pm="."><plain>The point of zero charge (PZC), that is, the pH values for which the surface charge density is zero, for bare IONPs may span several pH units depending on the type and concentration of charged species in the medium. </plain></SENT>
<SENT sid="127" pm="."><plain>For magnetite, it has been reported to range between 3.9 and 9.9 [20], and for maghaemite the reported range is around 3.3–7.5 depending on the reaction conditions [21]. </plain></SENT>
<SENT sid="128" pm="."><plain>Besides the PZC, another surface charge parameter of interest is the zeta-potential (ζ) [22][23], whose sign and value give an idea of the colloidal stability of NP suspensions rather than focusing exclusively on the isolated particles. </plain></SENT>
<SENT sid="129" pm="."><plain>It is commonly accepted that a stable colloidal suspension of IONPs has approximately ζ &lt; −30 mV or ζ &gt; +30 mV. </plain></SENT>
<SENT sid="130" pm="."><plain>Nevertheless, bare IONPs as such are of very limited interest for biomedical applications, due to their non-specificity, tendency to aggregation and short circulation times, as well as their toxicity, since they may induce vacuole formation and other cell damage leading to cell death [24]. </plain></SENT>
<SENT sid="131" pm="."><plain>In order to manipulate the surface charge, improve their biocompatibility and/or add a specific functionality (see section 2), IONPs can be coated with a large number of molecules by virtue of their relatively wide PZC range discussed above. </plain></SENT>
</text></p><p><text><SENT sid="132" pm="."><plain>The surface charge of both bare and coated IONPs influences the binding to cell membranes as the limiting step in their internalization process [25], irrespective of the shape. </plain></SENT>
<SENT sid="133" pm="."><plain>It is rather the sign of the charge that determines the internalization mechanism [26]. </plain></SENT>
<SENT sid="134" pm="."><plain>Membrane interaction can occur regardless of the charge of NPs, but it is well known that positively- or negatively-charged IONPs are internalized more rapidly than neutral ones. </plain></SENT>
<SENT sid="135" pm="."><plain>For instance, in vitro studies with L929 fibroblasts and Saos-2 osteoblasts reveal how the uptake of negatively-charged SPIONs (coated with dimercaptosuccinic acid, DMSA) and positively-charged SPIONs (coated with (3-aminopropyl) triethoxysilane, APS) is far superior to that of neutral SPIONs (coated with dextran) [27]. </plain></SENT>
<SENT sid="136" pm="."><plain>This charge-mediated internalization enhancement may lead to cell damage for concentrations of DMSA and APS-coated SPIONs above 0.10 mg/mL in L929 fibroblasts and 0.20 mg/mL in Saos-2 osteoblasts. </plain></SENT>
<SENT sid="137" pm="."><plain>Mahmoudi et al have found that positively-charged SPIONs promote amyloid-β protein fibrillation at significantly lower particle concentrations than neutral or negatively-charged SPIONs [28]. </plain></SENT>
</text></p><p><text><SENT sid="138" pm="."><plain>A good example of how surface charge may affect the fate of similar IONPs formulations inside mammalians arises from the comparison of ferumoxides (ζ = −32 mV), ferumoxytol (ζ = −49 mV) and ferumoxtran (ζ = −2 to 0 mV). </plain></SENT>
<SENT sid="139" pm="."><plain>The latter has a thicker dextran layer [29] to avoid opsonization (protein adsorption) typically seen in very small particles and increase its circulation time, but in exchange is internalized to a lesser extent due to its almost neutral ζ. On the other hand, ferumoxides and ferumoxytol do not adsorb proteins and do not readily become opsonized, but are removed from circulation by the reticuloendothelial (RES) system due to their negative ζ. </plain></SENT>
</text></p></sec></sec><sec id="section6-58841"><title><text><SENT sid="141" pm="."><plain>3. </plain></SENT>
<SENT sid="142" pm="."><plain>Functionalization of IONPs </plain></SENT>
</text></title><p><text><SENT sid="143" pm="."><plain>Functionalization of IONPs with biomolecules is a subject of great interest for two aspects related to their clinical applications. </plain></SENT>
<SENT sid="144" pm="."><plain>First, IONPs can be used as nanocarriers for drug delivery to tackle drug resistance of cancer cells and to increase local drug concentrations. </plain></SENT>
<SENT sid="145" pm="."><plain>Second, IONPs can be functionalized with specific targeting agents in order to improve the selectivity of specific cells, such as cancer cells, and therefore improve the selectivity, reduce side effects and increase local concentrations of drugs and/or IONPs in the targeted tissue. </plain></SENT>
<SENT sid="146" pm="."><plain>All these strategies are involved in the development of new generations of functionalized and multifunctionalized NPs for biomedical applications that introduce selective targeting properties to such nanocarriers. </plain></SENT>
</text></p><p><text><SENT sid="147" pm="."><plain>The effect of targeting is strongly related to the enhancement of cellular uptake. </plain></SENT>
<SENT sid="148" pm="."><plain>Indeed, targeting strategies involve the recognition and binding to membrane receptors overexpressed on targeted cells, which changes the cellular uptake pathway and its efficiency. </plain></SENT>
<SENT sid="149" pm="."><plain>Several functionalization and targeting strategies have been developed in parallel with the latest advances in the discovery of new biomarkers specific to the different types of cells considered (e.g., cancer cells, cancer stem cells, etc.). </plain></SENT>
</text></p><p><text><SENT sid="150" pm="."><plain>Currently, no clinical trials are in progress concerning the use of functionalized IONPs in humans. </plain></SENT>
<SENT sid="151" pm="."><plain>However, almost all the scientific publications in the field mention the potential biomedical and clinical applications of functionalized IONPs considering the promising in vitro and in vivo results. </plain></SENT>
<SENT sid="152" pm="."><plain>Among the wide diversity of molecules that have been used for the functionalization of IONPs described hereafter, most are already accepted by the different drug regulation administrations or are now in late clinical trial phases. </plain></SENT>
<SENT sid="153" pm="."><plain>Similarly, the IONP-based formulations ferumoxytol and GastroMARK are also approved. </plain></SENT>
<SENT sid="154" pm="."><plain>Therefore, the combination of both IONPs and specific functionalities shows great potential in the near future for the generation of novel nanoformulations for clinical use. </plain></SENT>
</text></p><p><text><SENT sid="155" pm="."><plain>Here, we present an overview of the different molecules that are currently used for the functionalization of IONPs, highlighting some relevant examples and their potential in clinics (Table 2 and Figure 3). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="table2-58841" orientation="portrait" position="float"><label>Table 2.</label><caption><p><text><SENT sid="156" pm="."><plain>Examples of biomolecules approved for clinical applications or already in clinical trials that are used in IONPs functionalization research studies </plain></SENT>
</text></p></caption><alternatives><graphic xlink:href="10.5772_58841-table2"/><table frame="border" rules="all" width="100%"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>Type of biomolecule </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>Used name </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>Biological Target </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Clinical trials status </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>Remarks and references of IONPs functionalization in research studies </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>Cell Penetrating Peptides (CPPs) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>p28 (azurin fragment) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>DNA binding domain of p53 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>p28 alone in phase I (NCT01975116 and NCT00914914) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>No research studies with IONPs </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="4" colspan="1"><text><SENT sid="167" pm="."><plain>Small Peptides </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>Arginine-Glycine-Aspartic acid (RGD) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>Integrin receptor αvβ3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>Phase I/II for cancer diagnostic by positron emission tomography(NCT01806675, NCT00565721, NCT01492192, NCT01961583) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>Montet et al. 2006 Xie et al. 2008 Nazli et al. 2012 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="2" colspan="1"><text><SENT sid="175" pm="."><plain>Chlorotoxin (CTX) </plain></SENT>
</text></td><td align="center" rowspan="2" colspan="1"><text><SENT sid="176" pm="."><plain>Binding affinity for gliomas and neuroectodermal tumors </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>Phase I for cancer imaging and safety study </plain></SENT>
</text></td><td align="center" rowspan="2" colspan="1"><text><SENT sid="178" pm="."><plain>Sun et al 2008 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>(NCT00379132, NCT00733798, NCT00040573) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>Nucant pseudopeptide (N6L) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>Binding nucleolin and nucleophosmin </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>Phase I/IIa, Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy on Advanced Solid Tumors (NCT01711398) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>Latorre et al. 2014 (submitted) Destouches et al. 2011 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>Antibodies </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>Trastuzumab </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>Her2/neu receptor </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>Accepted by FDA and over the world (Herceptin as commercial formulation for breast cancer) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>Hu et al. 2005 </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>Aptamers </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>E10030 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>Anti-platelet-derived growth factor (anti PDGF-B) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>Phase III for Age-Related Macular Degeneration (in complement with other anti-VEGF drug) NCT01940900 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>No research studies with IONPs </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>Folic Acid </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>Folate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>Folate receptors </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>Several clinical studies of folic acid conjugated to anti-cancer drugs (NCT00485563, NCT00485563, NCT00291785, etc.) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>Fan et al. 2011 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><SecTag type="FIG"><fig id="fig3-58841" orientation="portrait" position="float"><label>Figure 3.</label><caption><p><text><SENT sid="203" pm="."><plain>Functionalization of IONPs Schematic representation to scale of IONPs and the structure of different molecules used for their functionalization Structures represented: IONPs doxorubicin RGD peptide (PDB ID: 3VI4) chlorotoxin (PDB ID: 1CHL) azurin p28 peptide (PDB ID: 4AZU) Nucant (N6L) [52] aptamer (PDB ID 4HQU) and antibody (PDB ID: 1IGT). </plain></SENT>
</text></p></caption><graphic xlink:href="10.5772_58841-fig3"/></fig></SecTag><sec id="section7-58841"><title><text><SENT sid="204" pm="."><plain>3.1 Cell-penetrating peptides (CPPs) </plain></SENT>
</text></title><p><text><SENT sid="205" pm="."><plain>Cell-penetrating peptides (CPPs), also known as protein transduction domains (PTDs) are up to 30-amino acid amphiphilic peptides that can be internalized by cells using mechanisms that require no energy and that can be receptor-mediated or not. </plain></SENT>
<SENT sid="206" pm="."><plain>Among the large variety of CPPs sequences, the presence of positively-charged amino acids and the amphiphilic character are the two common characteristics [30]. </plain></SENT>
<SENT sid="207" pm="."><plain>First used for intracellular delivery of macromolecules [31], CPPs are very interesting as drug and NPs intracellular delivery carriers. </plain></SENT>
<SENT sid="208" pm="."><plain>IONPs functionalized with different amounts of Tat peptide showed an exponential increase of cell uptake by increasing the number of CPPs grafted onto IONPs, concluding in a multivalent effect on the internalization [32]. </plain></SENT>
<SENT sid="209" pm="."><plain>The important parameters for the entrance of CPPs are positive charge and amphiphilic character. </plain></SENT>
<SENT sid="210" pm="."><plain>Martin et al. [33] and Cavalli et al. [34] studied the use of guanidine-based dendritic structures and synthetic peptides mimicking CPPs' properties for IONP functionalization. </plain></SENT>
<SENT sid="211" pm="."><plain>Both studies, with different cell lines, had comparable results to the ones observed with CPPs. </plain></SENT>
<SENT sid="212" pm="."><plain>The interest in using synthetic structures is due to their stability toward protease degradation. </plain></SENT>
<SENT sid="213" pm="."><plain>These examples show that the conjugation of IONPs with CPPs and analogue peptides with similar physical properties can be used to improve the cellular uptake of IONPs. </plain></SENT>
</text></p><p><text><SENT sid="214" pm="."><plain>Additionally, newly identified tumour-homing CPPs have been discovered, expanding the use of CPPs for selective tumour targeting [35][36]. </plain></SENT>
<SENT sid="215" pm="."><plain>The only cell-penetrating peptide that has been tested in clinical trials is the so-called p28 peptide, which is derived from azurin protein and induces an increase of p53 and consequently cell death by apoptosis [37]. </plain></SENT>
<SENT sid="216" pm="."><plain>A completed phase I study (NCT00914914) and an ongoing phase I study (NCT01975116) have been carried out with the p28 peptide used as an anticancer drug for different types of tumours [38]. </plain></SENT>
<SENT sid="217" pm="."><plain>As far as we know, this p28 peptide has never been tested for IONP functionalization or for targeting strategies. </plain></SENT>
</text></p></sec><sec id="section8-58841"><title><text><SENT sid="218" pm="."><plain>3.2 Antibodies and other proteins </plain></SENT>
</text></title><p><text><SENT sid="219" pm="."><plain>Antibodies are complex protein molecules that bind to specific antigens with high affinity. </plain></SENT>
<SENT sid="220" pm="."><plain>Antibodies can be developed to bind to almost any given antigen, for example, specific receptors expressed on the surface of cells, and are therefore very useful tools to target disease biomarkers. </plain></SENT>
<SENT sid="221" pm="."><plain>Apart from their use as anticancer agents [39], antibodies have been used in IONP functionalization for their targeting properties toward cancer cells for a decade. </plain></SENT>
<SENT sid="222" pm="."><plain>As shown in the preliminary and encouraging study of Kang et al. in 2002 [40], IONPs can be functionalized with an antibody against E-selectin, an adhesion molecule induced in cancer cells. </plain></SENT>
<SENT sid="223" pm="."><plain>The final nanostructure was able to bind HUVEC cells specifically when the overexpression of E-selectin is previously activated. </plain></SENT>
</text></p><p><text><SENT sid="224" pm="."><plain>Numerous research groups are interested in the functionalization of IONPs with trastuzumab, a commercial and approved antibody for breast cancer treatment [41], for the development of targeted therapeutic strategies. </plain></SENT>
<SENT sid="225" pm="."><plain>Most of the studies confirmed the selectivity of the antibody-functionalized IONPs toward cell lines overexpressing the Her2 receptor, depending on receptor expression level [42][43]. </plain></SENT>
<SENT sid="226" pm="."><plain>Vigor et al. showed similar results using another antibody that binds carcinoembryonic antigen (CEA), a receptor overexpressed in colorectal cancer cells [44]. </plain></SENT>
<SENT sid="227" pm="."><plain>The use of antibodies for intracellular uptake of IONPs is currently developing and several works have examined the cell line specifically targeting the enhancement of the uptake. </plain></SENT>
</text></p><p><text><SENT sid="228" pm="."><plain>Additionally, other proteins are being used to functionalize IONPs and improve the cellular uptake and cell targeting. </plain></SENT>
<SENT sid="229" pm="."><plain>The example of transferrin-functionalized IONPs to target cancer's overexpression of transferring receptors has been recently published by Piraux et al. in 2013 [45]. </plain></SENT>
</text></p></sec><sec id="section9-58841"><title><text><SENT sid="230" pm="."><plain>3.3 Targeting peptides </plain></SENT>
</text></title><p><text><SENT sid="231" pm="."><plain>Apart from macromolecules such as antibodies and CPPs, smaller peptides also interact with specific receptors in the cell membrane and increase the cellular uptake of the functionalized IONPs. </plain></SENT>
</text></p><p><text><SENT sid="232" pm="."><plain>Arginine-glycine-aspartic acid, also known as RGD peptide, binds to the integrin receptor (αvβ3) which is overexpressed in several cancer cell lines and is commonly used as a targeting agent. </plain></SENT>
<SENT sid="233" pm="."><plain>Several works show that the functionalization of IONPs with RGD peptide (in linear or cyclic conformation) induces a significant increase in the cell uptake, compared to bare IONPs, specifically for αvβ3 positive cell lines as in some cancer cell lines (BT-20 and HeLa) and no significant changes in αvβ3 negative cells (9L, MCF-7, or U87MG cells) [46][47][48]. </plain></SENT>
<SENT sid="234" pm="."><plain>Similarly, chlorotoxin (CTX) is a 36-amino acid peptide that has a high selectivity and binding affinity for gliomas and neuroectodermal tumours [49]. </plain></SENT>
<SENT sid="235" pm="."><plain>Sun et al. showed a tenfold increase in the cellular uptake of CTX-functionalized IONPs compared to bare IONPs in 9L cells [50]. </plain></SENT>
<SENT sid="236" pm="."><plain>Nucant pseudopeptide (N6L) is a 4-kDa pseudopeptide currently in phase II clinical trials (NCT01711398), while the MultiFun European project (EU-FP7 no. 262943) is currently working on the multifunctionalization of IONPs with N6L and anticancer drugs. </plain></SENT>
<SENT sid="237" pm="."><plain>The significance of this pseudopeptide is that it acts as a targeting agent through its specific binding to nucleolin and nucleophosmin (overexpressed in several cancers) and also as a therapeutic agent [51][52]. </plain></SENT>
<SENT sid="238" pm="."><plain>The first results obtained showed the targeted uptake of N6L covalently-functionalized IONPs and the controlled release of N6L in a reducing medium which mimics the intracellular environment </plain></SENT>
</text></p></sec><sec id="section10-58841"><title><text><SENT sid="239" pm="."><plain>3.4. </plain></SENT>
<SENT sid="240" pm="."><plain>Aptamers </plain></SENT>
</text></title><p><text><SENT sid="241" pm="."><plain>Aptamers are single-stranded oligonucleotides that bind to their specific targets with high efficiency. </plain></SENT>
<SENT sid="242" pm="."><plain>Aptamers have been used for the targeting and specific cellular uptake of IONPs, as they present several advantages, such as their easy and reproducible synthesis, their good stability and their lack of immune response. </plain></SENT>
<SENT sid="243" pm="."><plain>Chen et al., in 2011, developed PEG-IONPs functionalized with doxorubicin and sg8c aptamer. </plain></SENT>
<SENT sid="244" pm="."><plain>Sg8c binds to the cell membrane receptor protein tyrosine kinase 7 (PTK7). </plain></SENT>
<SENT sid="245" pm="."><plain>The study showed a clear specificity of sg8c-functionalized IONPs for PTK7 positive cells compared to PTK7 negative cells in correlation with the cytotoxicity of released doxorubicin under high pH of lysosome medium, which also showed a receptor-mediated entrance [53]. </plain></SENT>
</text></p></sec><sec id="section11-58841"><title><text><SENT sid="246" pm="."><plain>3.5 Carbohydrates </plain></SENT>
</text></title><p><text><SENT sid="247" pm="."><plain>Functionalization of IONPs with carbohydrates can improve cellular uptake by two different strategies: (1) providing higher hydrophilicity and biocompatibility and thus increasing lifetime in the bloodstream; and (2) the interaction with specific sugar receptors on the membrane of certain cell lines, including cancer cells [54]. </plain></SENT>
<SENT sid="248" pm="."><plain>Moros et al. studied the uptake of IONPs functionalized with monosaccharides (glucose or galactose) compared to IONPs functionalized with PEG and showed that the type of carbohydrate affects the rate and the mechanism of internalization [55]. </plain></SENT>
<SENT sid="249" pm="."><plain>In 2011, Valero et al. also showed interesting results using IONPs encapsulated within apoferritin (apomaghemite) and then functionalized with two carbohydrates, N-acetyl-D-glucosamine and D-mannose. </plain></SENT>
<SENT sid="250" pm="."><plain>First, they found similar behaviour to an MRI contrast agent such as the commercial agent Endorem. </plain></SENT>
<SENT sid="251" pm="."><plain>Finally, they also observed that both carbohydrate-functionalized apomaghemite NPs retained the carbohydrate lectin recognition activity [56]. </plain></SENT>
</text></p></sec><sec id="section12-58841"><title><text><SENT sid="252" pm="."><plain>3.6 Folic acid </plain></SENT>
</text></title><p><text><SENT sid="253" pm="."><plain>Folic acid, also known as Vitamin B9, is a natural product with an important role in DNA and RNA synthesis. </plain></SENT>
<SENT sid="254" pm="."><plain>Over 20 years, folate receptors have been shown to be overexpressed on several cancer cell lines and can therefore be used for targeting cancer cells and activated macrophages [57][58]. </plain></SENT>
<SENT sid="255" pm="."><plain>Folic acid has already been approved for several clinical applications. </plain></SENT>
<SENT sid="256" pm="."><plain>Clinical trials are in progress for drug-folate conjugate use in cancer diagnosis (NCT00003763) and therapy (NCT00291785, NCT00485563, NCT00441870). </plain></SENT>
<SENT sid="257" pm="."><plain>Folic acid has been widely used for 15 years in the development of NP targeting strategies for biomedical applications, including IONPs. </plain></SENT>
<SENT sid="258" pm="."><plain>We highlight the work of Fan et al. in 2011, where a significant enhancement of cellular uptake of the folic acid-functionalized IONPs is achieved compared to bare IONPs, depending on the receptor expression levels of the cell lines used. </plain></SENT>
<SENT sid="259" pm="."><plain>Promising results of MRI in vivo highlight the potential of folic acid-functionalized IONPs for clinical applications [59]. </plain></SENT>
</text></p></sec><sec id="section13-58841"><title><text><SENT sid="260" pm="."><plain>3.7 Drugs </plain></SENT>
</text></title><p><text><SENT sid="261" pm="."><plain>The functionalization of IONPs with drugs for their application as nanocarriers is a wide and much studied topic [60]. </plain></SENT>
<SENT sid="262" pm="."><plain>Indeed, the major portion of the drugs used in combination with IONPs at the research level are already available in clinics, such as doxorubicin, gemcitabine and SN38, and are also involved in several clinical trials of drug-targeting agent conjugates. </plain></SENT>
<SENT sid="263" pm="."><plain>Currently, there are some promising examples of doxorubicin conjugated with antibodies now in clinical trials (NCT00051584), and the use of liposomal formulations for drug delivery (NCT01227941). </plain></SENT>
</text></p><p><text><SENT sid="264" pm="."><plain>The multifunctionalization of IONPs by targeting agents and drugs, and its acceptance in clinical processes, might be a breakthrough in the development of specific therapies. </plain></SENT>
<SENT sid="265" pm="."><plain>The presence of targeting moieties such as those discussed above will increase the localization of IONPs in the diseased tissue, therefore augmenting drug delivery and local drug concentration. </plain></SENT>
<SENT sid="266" pm="."><plain>Thus, research is currently making efforts towards the multifunctionalization of IONPs. </plain></SENT>
<SENT sid="267" pm="."><plain>Different methodologies need to be developed to ensure controlled multifunctionalization, and preserve the stability and biological activities of active molecules attached to the particles. </plain></SENT>
<SENT sid="268" pm="."><plain>Additionally, with respect to the clinical application of these nanostructures, functionalization efforts are required to increase the blood half-life of the IONPs, minimizing off-target accumulation and immunological response. </plain></SENT>
</text></p></sec></sec><sec id="section14-58841"><title><text><SENT sid="269" pm="."><plain>4. </plain></SENT>
<SENT sid="270" pm="."><plain>Toxicological profiles and potential interference with biological functions of cells </plain></SENT>
</text></title><p><text><SENT sid="271" pm="."><plain>The above-mentioned parameters have a tremendous influence on cell internalization as well as in vivo behaviour, and hence in the administration procedure of choice for clinical applications [61]. </plain></SENT>
<SENT sid="272" pm="."><plain>Mammalian cells internalize IONPs mainly through endocytosis mechanisms. </plain></SENT>
<SENT sid="273" pm="."><plain>However, the specific pathway depends on the cell type and physicochemical features of the IONPs. </plain></SENT>
<SENT sid="274" pm="."><plain>Most cells use different molecular pathways of pinocytosis, whereas cells from the reticuloendothelial system (RES) preferentially internalize IONPs by phagocytosis in a process that begins with the opsonization of the NPs in the bloodstream, followed by binding of the opsonized NPs to the cell surface and final ingestion [62] (Figure 4A). </plain></SENT>
<SENT sid="275" pm="."><plain>The IONPs approved for clinical use are not functionalized, but they display a variety of sizes that influence their administration and distribution within the body. </plain></SENT>
<SENT sid="276" pm="."><plain>SPIONs and USPION accumulate in the lungs, liver, spleen, lymph nodes, bone marrow vessels and capillaries, while VSPIONs also accumulate in the kidneys (Figure 4B). </plain></SENT>
<SENT sid="277" pm="."><plain>Once in the body, the iron of the NP core is stored in the red blood cells and, like the endogenous iron, it is progressively eliminated via faeces, while the coating (mostly dextran-derived compounds) degrades and is eliminated by the kidneys. </plain></SENT>
<SENT sid="278" pm="."><plain>However, the IONPs interact with different biological systems in the body and may have adverse effects. </plain></SENT>
<SENT sid="279" pm="."><plain>Evaluating the toxicological effects of IONPs both in vitro and in vivo is crucial for the development of IONP-derived applications in medicine. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig4-58841" orientation="portrait" position="float"><label>Figure 4.</label><caption><p><text><SENT sid="280" pm="."><plain>A. </plain></SENT>
<SENT sid="281" pm="."><plain>Different internalization pathways of IONPs in mammalian cells. </plain></SENT>
<SENT sid="282" pm="."><plain>Possible mechanisms of uptake including macropinocytosis, caveolae- and clathrin-mediated endocytosis, phagocytosis, passive diffusion and other endocytosis pathways. </plain></SENT>
<SENT sid="283" pm="."><plain>After internalization, IONPs can produce cytotoxicity effects via a Fenton reaction. </plain></SENT>
<SENT sid="284" pm="."><plain>Hydroxyl radicals generated could damage DNA, proteins or lipids (8-OH-dG = 8 hydroxydeoxyguanosine, MDA = malondialdehyde, HNE = 4-hydroxy-2-nonenal), triggering genotoxicity. </plain></SENT>
<SENT sid="285" pm="."><plain>B. </plain></SENT>
<SENT sid="286" pm="."><plain>IONP administration in the human body, such as intrathecal, intratumoural, intravenous and intramuscular or subcutaneous methods. </plain></SENT>
</text></p></caption><graphic xlink:href="10.5772_58841-fig4"/></fig></SecTag><sec id="section15-58841"><title><text><SENT sid="287" pm="."><plain>4.1 Effects on cellular physiology </plain></SENT>
</text></title><sec id="section16-58841"><title><text><SENT sid="288" pm="."><plain>4.1.1 Mitochondrial stress </plain></SENT>
</text></title><p><text><SENT sid="289" pm="."><plain>One factor that can contribute to nanotoxicity is the size of the NPs. </plain></SENT>
<SENT sid="290" pm="."><plain>Smaller NPs have a greater reactive surface area than larger ones, are more chemically reactive, and produce greater numbers of reactive oxygen species (ROS) that include free radicals [63]. </plain></SENT>
<SENT sid="291" pm="."><plain>SPIONs also can induce (geno-)toxicity via generation of ROS. </plain></SENT>
<SENT sid="292" pm="."><plain>SPIONs are presumably degraded into iron ions within the lysosomes by hydrolysing enzymes effective at low pH [64]. </plain></SENT>
<SENT sid="293" pm="."><plain>This “free iron” can potentially cross the nuclear or mitochondrial membrane and, in the latter case, the free iron in the form of ferrous ions (Fe2+) can react with hydrogen peroxide and oxygen produced by the mitochondria to produce highly reactive hydroxyl radicals and ferric ions (Fe3+) via the Fenton reaction (Figure 3a). </plain></SENT>
<SENT sid="294" pm="."><plain>Therefore, hydroxyl radicals generated by the free iron could damage DNA, proteins, polysaccharides and lipids in vivo [65]. </plain></SENT>
<SENT sid="295" pm="."><plain>The cytotoxicity was also found to be dependent on various factors, such as type of surface coating or its breakdown products, chemical composition of cell medium, oxidation state of iron in SPION and protein–SPION interaction [24][66][67]. </plain></SENT>
<SENT sid="296" pm="."><plain>For example in IONPs, magnetite (Fe3O4) and maghaemite (Fe2O3) can show different cellular responses because of their ability to undergo oxidation/reduction reactions. </plain></SENT>
<SENT sid="297" pm="."><plain>In fact, magnetite has been shown to cause higher levels of oxidative DNA lesions in the A549 human lung epithelial cell line in the absence of decreased cell viability as compared to maghaemite, owing to its potential to undergo oxidation. </plain></SENT>
<SENT sid="298" pm="."><plain>It is hypothesized that the toxicity can, however, be decreased by coating magnetite NPs, resulting in fewer oxidative sites that are less reactive, thereby producing less DNA damage [66]. </plain></SENT>
</text></p></sec><sec id="section17-58841"><title><text><SENT sid="299" pm="."><plain>4.1.2 Effects on actin cytoskeleton architecture </plain></SENT>
</text></title><p><text><SENT sid="300" pm="."><plain>Intracellular accumulation of NPs can have profound effects on cell morphology. </plain></SENT>
<SENT sid="301" pm="."><plain>High levels of internalized particles can provoke cellular stress, inducing changes in the architecture of the actin cytoskeleton. </plain></SENT>
<SENT sid="302" pm="."><plain>An altered actin network displaying actin stress fibres can lead to a reduced proliferative capacity and cell spreading. </plain></SENT>
<SENT sid="303" pm="."><plain>It can also influence the migration and differentiation of stem cells. </plain></SENT>
</text></p><p><text><SENT sid="304" pm="."><plain>In the case of IONPs, it has been reported to interfere with actin and tubulin structures, inducing cell retraction, rounding and deposition of massive dense filament matters adjacent to the nucleus and vacuoles in the cytoplasm [68]. </plain></SENT>
</text></p></sec></sec><sec id="section18-58841"><title><text><SENT sid="305" pm="."><plain>4.2 Factors that can contribute to non-toxicity </plain></SENT>
</text></title><p><text><SENT sid="306" pm="."><plain>Size is clearly a key factor in determining the potential toxicity of a particle. </plain></SENT>
<SENT sid="307" pm="."><plain>However, it is not the only important factor. </plain></SENT>
<SENT sid="308" pm="."><plain>Other properties of nanomaterials that influence toxicity include chemical composition, shape, surface structure, surface charge, aggregation and solubility [63]. </plain></SENT>
<SENT sid="309" pm="."><plain>A study investigating the effect of different surface coatings on cell behaviour and morphology has shown that dextranmagnetite (Fe3O4) NPs result in cell death and reduced proliferation similar to that caused by uncoated IONPs [24]. </plain></SENT>
<SENT sid="310" pm="."><plain>Other authors have reported the formation of gas vesicles after exposure to the uncoated NPs, resulting in altered protein functions and changes in ionic equilibrium within the cells, which also promotes toxicity [69]. </plain></SENT>
</text></p></sec><sec id="section19-58841"><title><text><SENT sid="311" pm="."><plain>4.3 In vitro and in vivo toxicity of nanoparticles in 2D vs. 3D cell culture </plain></SENT>
</text></title><p><text><SENT sid="312" pm="."><plain>Common 2D cell cultures do not adequately represent the functions of 3D tissues that have extensive cell–cell and cell–matrix interactions, as well as markedly different diffusion/transport conditions. </plain></SENT>
<SENT sid="313" pm="."><plain>Hence, testing cytotoxicity in 2D cultures may not accurately reflect the actual toxicity of NPs and other nanostructures in the body [70]. </plain></SENT>
<SENT sid="314" pm="."><plain>For instance, recent studies on toxicity testing of magnetic NPs, using in vitro 2D cell culture, demonstrated high cytotoxic effects. </plain></SENT>
<SENT sid="315" pm="."><plain>However, when they were tested in animal models, no adverse effects were observed [71]. </plain></SENT>
<SENT sid="316" pm="."><plain>Therefore, in vitro 3D cell culture models have been introduced to bridge the gap between in vitro 2D cell culture and in vivo models. </plain></SENT>
<SENT sid="317" pm="."><plain>Some authors report that bare IONPs were more toxic at lower concentrations in 3D culture, compared with 2D culture cells. </plain></SENT>
<SENT sid="318" pm="."><plain>This may be due to the increased contact area between NPs and cells in 3D culture [72]. </plain></SENT>
</text></p><p><text><SENT sid="319" pm="."><plain>When IONPs enter the body, absorption can occur through interaction with biological components such as proteins and cells; afterwards, they can distribute into various organs where they may remain in the same nanostructure or become metabolized [73]. </plain></SENT>
<SENT sid="320" pm="."><plain>A systematic and thorough quantitative analysis of the pharmacokinetics (i.e., absorption, distribution, metabolism and excretion) of IONPs can lead to improvements in design of biocompatible IONPs, a better understanding of NPs' non-specificity toward tissues and cell types, and assessments of basic distribution and clearance that serve as the basis to understand their activity and potential toxicity [74]. </plain></SENT>
</text></p><p><text><SENT sid="321" pm="."><plain>The surface of IONPs is rapidly covered by selective sets of blood plasma proteins after injection. </plain></SENT>
<SENT sid="322" pm="."><plain>Small IONPs (&lt; 10 nm) are usually rapidly removed through extravasation and renal clearance, whereas large IONPs (&gt; 200 nm) are sequestered by the spleen via mechanical filtration [75]. </plain></SENT>
<SENT sid="323" pm="."><plain>The typical final biodistribution of IONPs is 80–90 in liver, 5–8% in spleen and 1–2% in bone marrow, due to the high number of macrophages contained in these organs [61]. </plain></SENT>
<SENT sid="324" pm="."><plain>IONPs were also found to be distributed in the brain, liver, spleen and lungs after their inhalation, demonstrating their ability to cross the blood–brain barrier [76] (Figure 4A). </plain></SENT>
</text></p></sec></sec><sec id="section20-58841"><title><text><SENT sid="325" pm="."><plain>5. </plain></SENT>
<SENT sid="326" pm="."><plain>Current clinical applications </plain></SENT>
</text></title><p><text><SENT sid="327" pm="."><plain>In December 1996, the United States Food and Drug Administration (FDA) approved GastroMARK (AMAG Pharmaceuticals), an aqueous suspension of silicone coated, superparamagnetic iron oxide NPs, intended for oral administration, as a magnetic resonance (MR) imaging contrast medium to enhance the delineation of the bowel to distinguish it from organs and tissues that are adjacent to it in the upper regions of the gastrointestinal tract (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">www.fda.gov</ext-link>). </plain></SENT>
<SENT sid="328" pm="."><plain>The approval of GastroMARK, together with a number of preclinical studies supporting the potential use of SPIONs in different medical applications, contributed significantly to expanding clinical research in nanomedicine. </plain></SENT>
<SENT sid="329" pm="."><plain>A number of new SPION-derived products were developed, some of which were also approved by the FDA and the European Commission (EC) for clinical use. </plain></SENT>
<SENT sid="330" pm="."><plain>Additionally, the increasing number of clinical trials using these new NPs expanded their potential medical applications. </plain></SENT>
<SENT sid="331" pm="."><plain>Sixteen years later, just two SPION-derived products are approved by the FDA and commercially available: GastroMARK and ferumoxytol (Table 3). </plain></SENT>
<SENT sid="332" pm="."><plain>In the following paragraphs, we will describe the current clinical applications of SPION-derived products, as well as the clinical trials testing them for promising applications such as cell tracking and hyperthermia. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="table3-58841" orientation="portrait" position="float"><label>Table 3.</label><caption><p><text><SENT sid="333" pm="."><plain>Iron oxide nanoparticles (ION) for clinical applications: the table displays the chronology of ION approved by the Food and Drug Administration (FDA) and/or the European Commission (EC), discontinued and/or production abandoned. </plain></SENT>
<SENT sid="334" pm="."><plain>Sinerem's Authorization Application was withdrawn by Guerbet (European partner of AMAG Pharma) in 2007. </plain></SENT>
<SENT sid="335" pm="."><plain>Ferumoxide was discontinued by AMAG Pharma in 2008 and the production of Retrovist was abandoned in 2009. </plain></SENT>
</text></p></caption><alternatives><graphic xlink:href="10.5772_58841-table3"/><table frame="border" rules="all" width="100%"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>Date </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>Events </plain></SENT>
</text></th><th align="right" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>Indication </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>Size </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>Adm. </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>1996 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>Lumirem (Gastromark (US)): approved by FDA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>Contrast agent for MRI for the gastrointestinal tract </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>50 nm </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>Oral </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>1996 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>Ferumoxides (Emdorem (EU) or Feridex 1.V.): approved by the FDA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>Contrast agent for MRI of liver lesions </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>120–180 nm </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>Injectable solution </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>2001 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>Ferucarbotran (Resovist or (Cliavist(EU)): approved for Europena Market </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>Contrast-enhanced MRI of the liver </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>45–60 nm </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>Injectable solution </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>2005 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>Ferumoxtram (Sinerem (EU) or (Combidex (US)): AMAG Pharma received an approvable letter from the FDA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>Detection and characterization of metastatic lymph nodes in patients with pelvic cancer </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>10–40 nm </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>Injectable solution </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>2006 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>Sinerem: submitted European Marketing Authorization Application </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>Detection and characterization of metastatic lymph nodes in patients with pelvic cancer </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>10–40 nm </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>Injectable solution </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>2009 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>Feraheme (Ferumoxytol): approbed by the FDA </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>Iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>20–50 nm </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>intravenous </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>2012 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>Feraheme (Ferumoxytol): approbed by the EC </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>Iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>20–50 nm </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>intravenous </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><sec id="section21-58841"><title><text><SENT sid="376" pm="."><plain>5.1 Imaging </plain></SENT>
</text></title><p><text><SENT sid="377" pm="."><plain>Clinic imaging technologies rely on the use in MRI, optical imaging/MRI and MRI/PEP. </plain></SENT>
<SENT sid="378" pm="."><plain>SPIONs function as a negative contrast agent, decreasing T2 signals and thus the signal intensity. </plain></SENT>
<SENT sid="379" pm="."><plain>They cause a magnetic field gradient that affects the surrounding protons of water molecules, disrupting the homogeneity of the magnetic field, which can be observed by MRI [77]. </plain></SENT>
<SENT sid="380" pm="."><plain>Additionally, SPIONs display lymphotropic properties, as phagocytes of the RES internalize them, causing local changes in magnetic properties. </plain></SENT>
<SENT sid="381" pm="."><plain>These features make the SPIONs an excellent alternative to complement current contrast agents in MRI, providing higher accuracy in some conditions such as autoimmune diseases, cardiovascular and cerebrovascular pathologies, and cancer (Table 4). </plain></SENT>
<SENT sid="382" pm="."><plain>Additionally, the low toxicity both in vitro and in vivo, and their feasibility in enhancing the contrast of cellular targets in MRI, make then suitable for in vivo tracking of transplanted cells (Figure 5) [78]. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="table4-58841" orientation="portrait" position="float"><label>Table 4.</label><caption><p><text><SENT sid="383" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> search with the number of results and reference ID. </plain></SENT>
<SENT sid="384" pm="."><plain>Search terms: Superparamagnetic OR Iron Oxide OR SPIO OR USPIO OR VSPIO. </plain></SENT>
</text></p></caption><alternatives><graphic xlink:href="10.5772_58841-table4"/><table frame="border" rules="all" width="100%"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> </plain></SENT>
</text></th><th align="center" colspan="5" rowspan="1"><text><SENT sid="386" pm="."><plain>Imaging </plain></SENT>
</text></th><th align="center" colspan="3" rowspan="1"><text><SENT sid="387" pm="."><plain>Therapy </plain></SENT>
</text></th></tr><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>Indication </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>Lymph nodes </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>Head and neck cancer </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>Cardiovascular and Cerebrovascular diseases </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>Autoimmune diseases </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>Cell tracking </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>Delivery </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>Anemia </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>Hyperthermia </plain></SENT>
</text></th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>April 2014 (53)Clinical Trial Identificator </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>10NCT01815333NTC00147238NTC00920023NCT01927887NCT00188695NCT00147238NCT01296139NCT00243594NCT00416455NCT00107484 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>7NCT01895829NCT0660543NCT00769093NCT01663090NCT00978562NCT00659126NCT00659334 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>7NCT01127113NCT01323296NCT01995799NCT01674257NCT01749280NCT00794092NCT02084303 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>4NCT01973517NCT00585936NCT02006108NCT01243320 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>6NCT00972946NCT01169935NCT01127113NCT00660543NCT00243594NCT00781872 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>3NCT01270139NCT01436123NCT01927887 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>14NCT01052779NCT01114217NCT01114139NCT00114204NCT01374919NCT01264679NCT01227616NCT01155388NCT01942460NCT00233597NCT00255437NCT01148745NCT00255450NCT01950247 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>2NCT02033447DRKS00005476 </plain></SENT>
</text></td></tr></tbody></table></alternatives></table-wrap></SecTag><SecTag type="FIG"><fig id="fig5-58841" orientation="portrait" position="float"><label>Figure 5.</label><caption><p><text><SENT sid="406" pm="."><plain>Organ distribution of systemically injected nanoparticles. a. Common organ distribution is shown as a function of particle size. b. Example of the 99mTc-labeled graft copolymer used in a human patient and 89Zr-labeled cross-linked dextran nanoparticles used in a mouse model. </plain></SENT>
<SENT sid="409" pm="."><plain>This figure was reproduced with permission from Nature Materials [126]. </plain></SENT>
</text></p></caption><graphic xlink:href="10.5772_58841-fig5"/></fig></SecTag><sec id="section22-58841"><title><text><SENT sid="410" pm="."><plain>5.1.1 Diagnostic tools </plain></SENT>
</text></title><sec id="section23-58841"><title><text><SENT sid="411" pm="."><plain>5.1.1.1 Diagnosis in immunological diseases </plain></SENT>
</text></title><p><text><SENT sid="412" pm="."><plain>Autoimmune disease and inflammation processes are characterized by the activation of the endothelium that eventually allows for the extravasation of macrophages from the bloodstream into the inflamed tissue. </plain></SENT>
<SENT sid="413" pm="."><plain>SPIONs significantly enhance the signal of these events when analysed by MRI, as they are quickly captured by macrophages. </plain></SENT>
<SENT sid="414" pm="."><plain>In the last few years, a number of authors have taken advantage of this observation and carried out different clinical assays to test the value of SPIONs as a negative contrast in a variety of autoimmune and inflammatory conditions. </plain></SENT>
<SENT sid="415" pm="."><plain>Oral USPION (ferumoxytol) improved the detection of Crohn's disease [79] and the prognosis of active ulcerative colitis [80][81]. </plain></SENT>
<SENT sid="416" pm="."><plain>Using ferumoxtran, a significant improvement was observed in a small cohort of Type 1A diabetes patients (NCT00585936) in the diagnosis of pancreatic islet inflammation when compared to T1-gadolinium [82]. </plain></SENT>
<SENT sid="417" pm="."><plain>In patients with multiple sclerosis, USPION-based MRI showed that iron oxide NPs labelled larger and better defined areas, allowing the detection of what has been referred to as normal-appearing white matter that is histologically affected (NCT01973517) [83][84]. </plain></SENT>
<SENT sid="418" pm="."><plain>These outstanding results have encouraged physicians and researchers to continue testing the SPION-based MRI in both the previous and new immunological and inflammatory conditions. </plain></SENT>
<SENT sid="419" pm="."><plain>At least two more clinical trials were running at the time of writing this review (Table 4). </plain></SENT>
</text></p></sec><sec id="section24-58841"><title><text><SENT sid="420" pm="."><plain>5.1.1.2 Diagnosis in cardiovascular and cerebrovascular pathologies </plain></SENT>
</text></title><p><text><SENT sid="421" pm="."><plain>The use of SPIONs for T2 and T2-weighted cardiovascular magnetic resonance imaging (CMR) has been successfully validated to detect myocardial oedema and myocardial haemorrhage [85][86]. </plain></SENT>
<SENT sid="422" pm="."><plain>In a more recent trial, Vilmaz et al. demonstrated that ferumoxytol significantly improved the signal in the myocardial infarction area when compared with gadolinium-based contrast images. </plain></SENT>
<SENT sid="423" pm="."><plain>This improvement was due to the accumulation of USPIONs in infiltrating macrophages [87]. </plain></SENT>
<SENT sid="424" pm="."><plain>Similarly, Sigovan et al. demonstrated that ferumoxytol-enhanced MR angiography rendered superior image quality compared with non-enhanced time-of-flight MR when studying upper extremity autogenous fistulas in patients with renal failure. </plain></SENT>
<SENT sid="425" pm="."><plain>The use of ferumoxytol reduced flow artefacts while simultaneously raising lumen depiction scores, thus obtaining a more homogeneous luminal signal enhancement [88]. </plain></SENT>
<SENT sid="426" pm="."><plain>The ability to detect macrophage activity of plaque inflammation by MRI has also supported the use of SPION-based MRI of carotid atherosclerosis to predict cerebrovascular and cardiovascular morbidity and mortality. </plain></SENT>
<SENT sid="427" pm="."><plain>The author found an interesting association between USPIO-defined plaque inflammation and the development of vascular events, although the association was not significant due, in part, to the relatively low baseline risk of vascular event of the patient included in the clinical trial [89]. </plain></SENT>
<SENT sid="428" pm="."><plain>However, the overall data available from different trials aim to leverage the SPION-based MRI to assess the diagnosis of cardiovascular and cerebrovascular pathology in the next year. </plain></SENT>
<SENT sid="429" pm="."><plain>Thus it will be very important to pay special attention to the results derived from the ongoing clinical trials (Table 4). </plain></SENT>
</text></p></sec><sec id="section25-58841"><title><text><SENT sid="430" pm="."><plain>5.1.1.3 Diagnosis in cancer </plain></SENT>
</text></title><p><text><SENT sid="431" pm="."><plain>In healthy liver, spleen and lymph node tissue, IONPs decrease the MR signal intensity as phagocytic cells uptake the nanoparticles, while malignant tissue generally fails to uptake IONPs and appears bright relative to the surrounding tissue [90][91]. </plain></SENT>
<SENT sid="432" pm="."><plain>This observation emphasizes the IONP-enhanced MRI as an extremely promising imaging technique for the preoperative detection of metastatic disease in lymph nodes. </plain></SENT>
<SENT sid="433" pm="."><plain>In 2003, Harisinghani et al. reported that high-resolution MRI with IONPs (Sinerem) allowed the detection of small and otherwise undetectable lymph-node metastases in patients with prostate cancer, demonstrating the sensitivity and specificity of the technique [92]. </plain></SENT>
<SENT sid="434" pm="."><plain>From this point of departure, a number of clinical trials have successfully tested the IONP-enhanced MRI to detect sentinel lymph nodes in prostate cancer [93][94], as well as other types of cancers like bladder [95], breast (Endorem [96] and Resovist [97][98]) and renal cell (Sinerem) [99], among others (Table 4). </plain></SENT>
</text></p></sec></sec><sec id="section26-58841"><title><text><SENT sid="435" pm="."><plain>5.1.2 Cell tracking in cell transplantation-mediated therapies </plain></SENT>
</text></title><p><text><SENT sid="436" pm="."><plain>Cell therapy relies on the delivery of cells to the target site. </plain></SENT>
<SENT sid="437" pm="."><plain>Monitoring and tracking these cells to ensure tissue delivery and engraftment become a key issue in stabilizing clinical safety and therapeutic efficacy. </plain></SENT>
<SENT sid="438" pm="."><plain>In this sense, detection by MRI of IONP-labelled cells may be one of the most promising approaches for a short-term evaluation [100]. </plain></SENT>
<SENT sid="439" pm="."><plain>Although the FDA and EC have not yet approved their use for in vivo cell tracking, a few clinical trials have evaluated their feasibility and safety in different contexts (NCT00972946, NCT01169935 and NCT01127113). </plain></SENT>
<SENT sid="440" pm="."><plain>To evaluate the feasibility, safety and immunological effects of intrathecal and intravenous administration of autologous mesenchymal stem cells in patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis, Karussis et al. designed and carried out a clinical trial in which MSC were magnetically labelled with ferumoxides. </plain></SENT>
<SENT sid="441" pm="."><plain>The MSC were incubated with ferumoxides in the presence of poly-L-lysine for 24 to 48 hours prior to transplantation. </plain></SENT>
<SENT sid="442" pm="."><plain>MRI examination of the brain and spinal cord was performed at 24 and 48 hours, and later at one to three months. </plain></SENT>
<SENT sid="443" pm="."><plain>The image revealed a possible migration of such cells to the meninges of the spinal cord and nerve roots, and to the spinal cord parenchyma, although they could not rule out the possibility that macrophages had phagocytized the iron oxide magnetic NPs and migrated to the inflammatory MS lesions [101]. </plain></SENT>
<SENT sid="444" pm="."><plain>In a different work, Richards et al. successfully SPION-labelled human peripheral blood mononuclear cells (PBMC) and performed intramuscular and intravenous administration of labelled cells in healthy volunteers without remarkable side effects. </plain></SENT>
<SENT sid="445" pm="."><plain>After administration of labelled cells, the signal intensity was reduced in the liver and spleen, reflecting dose-dependent accumulation of SPION-labelled cells. </plain></SENT>
<SENT sid="446" pm="."><plain>This work demonstrated that labelled cells can be visualized in vivo at clinically relevant field strengths after local or systemic administration, and that SPION-labelled cells can be tracked to a site of focal inflammation in humans. </plain></SENT>
<SENT sid="447" pm="."><plain>More importantly, however, they demonstrated that intravenous administration of SPION-labelled cells in humans is safe [78]. </plain></SENT>
</text></p><p><text><SENT sid="448" pm="."><plain>Cancer immunotherapy approaches can also benefit from SPION labelling technology. </plain></SENT>
<SENT sid="449" pm="."><plain>Dendritic cell (DC) vaccines have been used to induce tumour-specific cytotoxic T cells. </plain></SENT>
<SENT sid="450" pm="."><plain>To be successful, injected DCs need to migrate to the lymph nodes (LNs) where they can stimulate effector T cells. </plain></SENT>
<SENT sid="451" pm="."><plain>DCs have previously been labelled with radionuclides for scintigraphic imaging, which is the only clinical cellular imaging modality approved by the FDA [102][103]. </plain></SENT>
<SENT sid="452" pm="."><plain>deVris et al. investigated the biodistribution of SPION-labelled DCs applied as cancer vaccines in melanoma patients using MRI, and demonstrated that MRI allowed assessment of the accuracy of DC delivery and of inter- and intranodal cell migration patterns [104]. </plain></SENT>
</text></p></sec></sec><sec id="section27-58841"><title><text><SENT sid="453" pm="."><plain>5.2 Therapy </plain></SENT>
</text></title><sec id="section28-58841"><title><text><SENT sid="454" pm="."><plain>5.2.1 Delivery </plain></SENT>
</text></title><p><text><SENT sid="455" pm="."><plain>Iron oxide NPs have been successfully used as a carrier for bioactive molecules in a number of conditions both in vitro and in animal models [105]. </plain></SENT>
<SENT sid="456" pm="."><plain>In the last few years, SPIONs have also been demonstrated to be useful in clinical settings (NCT01270139, NCT01436123 and NCT01927887). </plain></SENT>
<SENT sid="457" pm="."><plain>In 2009 Provenzano et al. reported that rapid intravenous injection of ferumoxytol led to significantly greater haemoglobin increases compared with oral iron, and was also well tolerated in all patients [106]. </plain></SENT>
<SENT sid="458" pm="."><plain>The same year, ferumoxytol was approved by the FDA, and later in 2012 by the EC, as an iron replacement therapy indicated for the treatment of iron deficiency anaemia in adult patients with chronic kidney disease. </plain></SENT>
<SENT sid="459" pm="."><plain>Since then, a number of clinical trials have extended the use of ferumoxytol as intravenous iron delivery/therapy to other iron deficiency conditions. </plain></SENT>
<SENT sid="460" pm="."><plain>Ferumoxytol was effective and well tolerated in adult patients with iron deficiency anaemia in whom oral iron was ineffective or could not be used [107][108], and showed comparable efficacy and adverse event rates to the first choice, iron sucrose [109], even in paediatric patients [110]. </plain></SENT>
</text></p></sec><sec id="section29-58841"><title><text><SENT sid="461" pm="."><plain>5.2.2 Hyperthermia </plain></SENT>
</text></title><p><text><SENT sid="462" pm="."><plain>Thermotherapy of solid tumours is one of the most promising applications of SPIONs, either alone or in combination with adjuvant treatments, such as chemotherapy or radiation. </plain></SENT>
<SENT sid="463" pm="."><plain>The principle of applying IONPs to hyperthermia therapy involves the administration of an IONPs fluid within the tumour, followed by the application of an alternating magnetic field. </plain></SENT>
<SENT sid="464" pm="."><plain>These nanoparticles achieve high temperatures, promoting warming of the region. </plain></SENT>
<SENT sid="465" pm="."><plain>Temperature elevation in the range of 41–46 °C can induce several effects at both cellular and tissue levels [111]. </plain></SENT>
<SENT sid="466" pm="."><plain>Cellular hyperthermia induces heat stress, resulting in high level of heat-shock protein expression, protein denaturation and folding and apoptosis. </plain></SENT>
<SENT sid="467" pm="."><plain>At the tissue level, temperature elevation induces changes in pH, perfusion and oxygenation of the tumour microenvironment [112][113], while higher temperature (hyperthermia) or longer treatment time may lead to necrosis. </plain></SENT>
</text></p><p><text><SENT sid="468" pm="."><plain>Clinical studies for the application of thermotherapy using IONPs in humans were initiated in 2007 on prostate cancer and glioblastoma patients (NCT02033447 and DRKS00005476). </plain></SENT>
<SENT sid="469" pm="."><plain>Johannsen et al. injected the IONPs fluid transperineally into the prostate of ten patients who received six thermal therapies of 60 minutes duration at weekly intervals. </plain></SENT>
<SENT sid="470" pm="."><plain>They reached maximum temperatures of 55 °C in the prostate with a median temperature of 40.7 °C within the tumour and 40.2 °C in peritumoural zones. </plain></SENT>
<SENT sid="471" pm="."><plain>With this assay they demonstrated the feasibility of thermotherapy [114]. </plain></SENT>
<SENT sid="472" pm="."><plain>Afterwards, they carried out a different clinical assay demonstrating that interstitial heating using IONPs was feasible and well tolerated in patients with locally recurrent prostate cancer, and the deposition of nanoparticles in the prostate was highly durable [52]. </plain></SENT>
</text></p><p><text><SENT sid="473" pm="."><plain>In parallel, Maier-Hauff et al. evaluated the feasibility and tolerability of thermotherapy in patients with recurrent glioblastoma multiforme. </plain></SENT>
<SENT sid="474" pm="."><plain>In this trial, patients received four to 10 thermotherapy treatments, reaching a median intratumoural temperature of 44.6 °C. </plain></SENT>
<SENT sid="475" pm="."><plain>The authors observed that thermotherapy using IONPs was tolerated well by all patients with minor or no side effects [115]. </plain></SENT>
<SENT sid="476" pm="."><plain>A few years later, they carried out another clinical trial and observed that the median overall survival following diagnosis of first tumour recurrence was 13.4 months, which was an improvement compared to the 6.2 months in other reference studies in the field. </plain></SENT>
<SENT sid="477" pm="."><plain>Additionally, the median of overall survival after primary tumour diagnosis was 23.2 months, compared with just 14.6 in the reference groups [116]. </plain></SENT>
</text></p><p><text><SENT sid="478" pm="."><plain>More recently, Matsumine et al. reported the utilization of hyperthermia in patients with metastatic bone tumours. </plain></SENT>
<SENT sid="479" pm="."><plain>The authors carried out an initial surgical intervention followed by the implantation of a mixture of “bare” magnetite NPs and calcium phosphate cement, which is a biocompatible bone substitute. </plain></SENT>
<SENT sid="480" pm="."><plain>The patients were treated for 15 minutes every two days starting from the eighth day after surgery. </plain></SENT>
<SENT sid="481" pm="."><plain>Thirty-two percent of lesions were reduced and presented visible bone formation, 64% showed no progressive lesions for more than three months and just 4% presented a poor response to the treatment, demonstrating safety and effectiveness [117]. </plain></SENT>
</text></p><p><text><SENT sid="482" pm="."><plain>Although these results are promising, the development of therapies based on magnetic hyperthermia is still in its very early stages. </plain></SENT>
<SENT sid="483" pm="."><plain>In the next few years, many biological and technical advances need to be achieved before this new therapy becomes part of the standard of care for some cancers. </plain></SENT>
<SENT sid="484" pm="."><plain>Questions such as how to reach homogenous distribution of IONPs and therapeutic temperature, and how to minimize peritumoural tissue damage, need to be addressed. </plain></SENT>
<SENT sid="485" pm="."><plain>In this regard, a new phase 0 clinical trial to investigate the magnetic nanoparticle thermo-ablation-retention and maintenance in the prostate is being performed by the University College London Hospitals (NCT 02033447). </plain></SENT>
<SENT sid="486" pm="."><plain>In this trial, the authors will test whether the magnetic nanoparticles actually stay where they are injected or move to sensitive structures around the prostate, which may lead to undesirable side effects. </plain></SENT>
<SENT sid="487" pm="."><plain>Finally, MagForce is conducting a new open-label, randomized clinical trial employing magnetic hyperthermia to treat glioblastoma multiforme patients (DRKS00005476). </plain></SENT>
<SENT sid="488" pm="."><plain>The purpose of this trial, expected to enrol up to 285 patients, is to test the feasibility and safety of using magnetic hyperthermia as a stand-alone therapy and in combination with radiotherapy using the commercial IONPs NanoTherm®. </plain></SENT>
<SENT sid="489" pm="."><plain>The results will help magnetic hyperthermia advance in the clinical setting. </plain></SENT>
</text></p></sec></sec></sec><SecTag type="DISCUSS"><sec id="section30-58841"><title><text><SENT sid="490" pm="."><plain>6. </plain></SENT>
<SENT sid="491" pm="."><plain>Perspectives </plain></SENT>
</text></title><p><text><SENT sid="492" pm="."><plain>Bare IONPs are currently employed in an increasing number of clinical trials. </plain></SENT>
<SENT sid="493" pm="."><plain>In the next decade, we will see them settle into clinical practice for imaging-based diagnosis for a wide range of diseases. </plain></SENT>
<SENT sid="494" pm="."><plain>One of the main entries of IONPs into the scene of medical application will surely come from their functionalization possibilities. </plain></SENT>
<SENT sid="495" pm="."><plain>These will provide them with the capacity to target specific cells within the body, and hence develop specific therapies and diagnostic tools. </plain></SENT>
<SENT sid="496" pm="."><plain>The main advantages of using nanocarriers for specific drug delivery are the reduction of side effects, potential drug resistance and increased drug payload. </plain></SENT>
<SENT sid="497" pm="."><plain>As unique targeted nanocarriers can deliver hundreds of small drug molecules, clinical practices shall be adapted to incorporate these new strategies. </plain></SENT>
<SENT sid="498" pm="."><plain>They should include treatment protocols personalized by choosing appropriate formulations with defined targeting moieties and drug loads. </plain></SENT>
<SENT sid="499" pm="."><plain>The multifunctionalization of IONPs opens the door to multimodal therapeutic approaches by combining the dual effects of magnetic hyperthermia and chemotherapy, using multiple drugs in the same IONP formulation. </plain></SENT>
<SENT sid="500" pm="."><plain>Additionally, functionalization of IONPs will allow researchers to tune and optimize IONPs' biocompatibility, blood half-life and immunogenicity, key parameters required to successfully bring these innovative nanotechnology-based tools from research laboratories to clinics. </plain></SENT>
<SENT sid="501" pm="."><plain>Overall, the multifunctionalization of IONPs is a critical step. </plain></SENT>
<SENT sid="502" pm="."><plain>It is most likely that it will be broadly implemented in the near future for new nanoformulations for both diagnosis and therapy. </plain></SENT>
</text></p><p><text><SENT sid="503" pm="."><plain>In the particular case of IONPs for magnetic hyperthermia, a number of fundamental and practical aspects still require more research. </plain></SENT>
<SENT sid="504" pm="."><plain>One of these concerns the magnetic and mechanical behaviour of IONPs inside cells: specifically, we refer to lysosomes under dynamic external fields. </plain></SENT>
<SENT sid="505" pm="."><plain>Although a few theoretical studies addressing this matter have appeared [118], we require specific experimental approaches to confirm their predictions. </plain></SENT>
<SENT sid="506" pm="."><plain>Additionally, more work needs to be done to determine the actual heating mechanisms under common frequency and field amplitude conditions, and to evaluate the involvement of any other physical phenomena. </plain></SENT>
<SENT sid="507" pm="."><plain>In this sense, the results from a very recent publication exploring possible damage to the lysosomal membrane by a remotely induced torque over IONPs are particularly encouraging [119]. </plain></SENT>
<SENT sid="508" pm="."><plain>The role of phonon-mediated heating and its coupling to those biomolecules in the surroundings, or directly linked to IONPs, is now receiving more attention [120]. </plain></SENT>
<SENT sid="509" pm="."><plain>These studies will enable us to discern whether or not a sizeable macroscopic temperature change is required to have a therapeutic effect. </plain></SENT>
<SENT sid="510" pm="."><plain>If not, temperature changes on the micro- or nano-scale could be enough to induce cell death or, at least, to sensitize cancer cells to other treatments (chemo/radiotherapy). </plain></SENT>
<SENT sid="511" pm="."><plain>Finally, the possibility of having magnetic hyperthermia in an MRI machine has been proposed [121–122], but no clear steps have been taken to further develop this appealing idea. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>7. Acknowledgments</title><p><text4fund><text><SENT sid="512" pm="."><plain>We are especially grateful to the Health Research Fund (Fondo de Investigaciones Sanitarias, FIS) from the Carlos III Health Institute (PI10/01069 and CP11/00147 (AAS) and PI11/00537 (CBI)). </plain></SENT>
<SENT sid="513" pm="."><plain>AAS is a recipient of the Miguel Servet Program from Carlos III Health Institute (MS11/00147). </plain></SENT>
<SENT sid="514" pm="."><plain>DO is grateful for the support received through the AMAROUT-II Marie Curie Action under the European Commission's FP7 PEOPLE-COFUND program and the Research Fund grant from the Royal Society of Chemistry. </plain></SENT>
<SENT sid="515" pm="."><plain>ALC is grateful for the financial support received through the EU-FP7 MULTIFUN project (no. 262943), the Spanish Ministerio de Economía y Competitividad (BIO2012–34835), the European Commission International Reintegration Grant (IRG-246688) and the Marie Curie COFUND “AMAROUT-Europe” Programme. </plain></SENT>
</text></text4fund></p></ack></SecTag><sec id="section32-58841" sec-type="COI-statement"><title>8. Compliance with ethical research standards</title><p>Authors have no conflict of interest to declare. No part of this study was performed on any human or animal subject.</p></sec><SecTag type="REF"><ref-list><title>References</title><ref id="bibr1-58841"><text><SENT sid="516" pm="."><plain>[1]KrishnanKM Biomedical nanomagnetics: A spin through possibilities in imaging, diagnostics, and therapy. IEEE Trans. </plain></SENT>
<SENT sid="517" pm="."><plain>Magn. 46, 2523–2558 (2010). </plain></SENT>
</text></ref><ref id="bibr2-58841"><text><SENT sid="518" pm="."><plain>[2]CoeyJMD Magnetism and Magnetic Materials. Cambridge University Press 2010. </plain></SENT>
</text></ref><ref id="bibr3-58841"><text><SENT sid="519" pm="."><plain>[3]LingDHyeonT. Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small [Internet] 9(9–10), 1450–1466 (2013). </plain></SENT>
<SENT sid="520" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/smll.201202111">http://dx.doi.org/10.1002/smll.201202111</ext-link>. </plain></SENT>
</text></ref><ref id="bibr4-58841"><text><SENT sid="521" pm="."><plain>[4]BaazizWPichonBPFleutotS Magnetic iron oxide nanoparticles: Reproducible tuning of the size and nanosized-dependent composition, defects, and spin canting. J. Phys. </plain></SENT>
<SENT sid="523" pm="."><plain>Chem. </plain></SENT>
<SENT sid="524" pm="."><plain>C. 118(7), 3795–3810. </plain></SENT>
<SENT sid="525" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84894560846&amp;partnerID=40&amp;md5=f738e89fe887bd8209d8a92fb3de1a7d">http://www.scopus.com/inward/record.url?eid=2-s2.0-84894560846&amp;partnerID=40&amp;md5=f738e89fe887bd8209d8a92fb3de1a7d</ext-link>. </plain></SENT>
<SENT sid="526" pm="."><plain>Accessed on 21 Jan 2014. </plain></SENT>
</text></ref><ref id="bibr5-58841"><text><SENT sid="527" pm="."><plain>[5]HeQYuanTYanX One-pot synthesis of size-and morphology-controlled 1-D iron oxide nanochains with manipulated magnetic properties. Chem. </plain></SENT>
<SENT sid="528" pm="."><plain>Commun. 50(2), 201–203 (2014). </plain></SENT>
<SENT sid="529" pm="."><plain>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84889034764&amp;partnerID=40&amp;md5=409176aec077443f92e6d731dd0437f7">http://www.scopus.com/inward/record.url?eid=2-s2.0-84889034764&amp;partnerID=40&amp;md5=409176aec077443f92e6d731dd0437f7</ext-link>. </plain></SENT>
<SENT sid="530" pm="."><plain>Accessed on 23 Oct 2013. </plain></SENT>
</text></ref><ref id="bibr6-58841"><text><SENT sid="531" pm="."><plain>[6]ZhangLDongWFSunHB Multifunctional superparamagnetic iron oxide nanoparticles: Design, synthesis and biomedical photonic applications. Nanoscale 5, 7664–7684 (2013).23877222 </plain></SENT>
</text></ref><ref id="bibr7-58841"><text><SENT sid="532" pm="."><plain>[7]GeraldesCFLaurentS. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol. </plain></SENT>
<SENT sid="533" pm="."><plain>Imaging 4(1), 1–23 (2009).19156706 </plain></SENT>
</text></ref><ref id="bibr8-58841"><text><SENT sid="534" pm="."><plain>[8]PuriIKGangulyR. Particle transport in therapeutic magnetic fields. Annual Review of Fluid Mechanics 46, 407–440 (2014). </plain></SENT>
</text></ref><ref id="bibr9-58841"><text><SENT sid="535" pm="."><plain>[9]BarrySE Challenges in the development of magnetic particles for therapeutic applications. Int. </plain></SENT>
<SENT sid="536" pm="."><plain>J. </plain></SENT>
<SENT sid="537" pm="."><plain>Hyperth. 24(6), 451–466 (2008). </plain></SENT>
</text></ref><ref id="bibr10-58841"><text><SENT sid="538" pm="."><plain>[10]ShiWWangJFanXGaoH. Size and shape effects on diffusion and absorption of colloidal particles near a partially absorbing sphere: Implications for uptake of nanoparticles in animal cells. Phys. </plain></SENT>
<SENT sid="539" pm="."><plain>Rev. </plain></SENT>
<SENT sid="540" pm="."><plain>E -Stat. </plain></SENT>
<SENT sid="541" pm="."><plain>Nonlinear, Soft Matter Phys. 78(6) (2008). </plain></SENT>
</text></ref><ref id="bibr11-58841"><text><SENT sid="542" pm="."><plain>[11]LiX. Size and shape effects on receptor-mediated endocytosis of nanoparticles. J. Appl. </plain></SENT>
<SENT sid="544" pm="."><plain>Phys. 111(2) (2012). </plain></SENT>
</text></ref><ref id="bibr12-58841"><text><SENT sid="545" pm="."><plain>[12]GuimarãesAP Principles of Nanomagnetism. NanoScience and Nanotechnology series, Springer. (2009). </plain></SENT>
</text></ref><ref id="bibr13-58841"><text><SENT sid="546" pm="."><plain>[13]CowburnRPKoltsovDKAdeyeyeAOWellandMETrickerDM Single-domain circular nanomagnets. Phys. </plain></SENT>
<SENT sid="547" pm="."><plain>Rev. </plain></SENT>
<SENT sid="548" pm="."><plain>Lett. 83, 1042–1045 (1999). </plain></SENT>
</text></ref><ref id="bibr14-58841"><text><SENT sid="549" pm="."><plain>[14]AharoniA. The concept of single-domain particle. IEEE Trans. </plain></SENT>
<SENT sid="550" pm="."><plain>Magn. 27, 4775–4777 (1991). </plain></SENT>
</text></ref><ref id="bibr15-58841"><text><SENT sid="551" pm="."><plain>[15]ShiWWangJFanXGaoH. Size and shape effects on diffusion and absorption of colloidal particles near a partially absorbing sphere: Implications for uptake of nanoparticles in animal cells. Phys. </plain></SENT>
<SENT sid="552" pm="."><plain>Rev. </plain></SENT>
<SENT sid="553" pm="."><plain>E -Stat. </plain></SENT>
<SENT sid="554" pm="."><plain>Nonlinear, Soft Matter Phys. 78(6) (2008). </plain></SENT>
</text></ref><ref id="bibr16-58841"><text><SENT sid="555" pm="."><plain>[16]DasguptaSAuthTGompperG. Shape and orientation matter for the cellular uptake of nonspherical particles. Nano Lett. 14(2), 687–693 (2014).24383757 </plain></SENT>
</text></ref><ref id="bibr17-58841"><text><SENT sid="556" pm="."><plain>[17]GaoH. Probing mechanical principles of cell-nanomaterial interactions. J. Mech. </plain></SENT>
<SENT sid="558" pm="."><plain>Phys. </plain></SENT>
<SENT sid="559" pm="."><plain>Solids. 62(1), 312–339 (2014. </plain></SENT>
</text></ref><ref id="bibr18-58841"><text><SENT sid="560" pm="."><plain>[18]ShiXvon dem BusscheAHurtRHKaneABGaoH. Cell entry of one-dimensional nanomaterials occurs by tip recognition and rotation. Nat. </plain></SENT>
<SENT sid="561" pm="."><plain>Nano. 6(11), 714–719 (2011). </plain></SENT>
</text></ref><ref id="bibr19-58841"><text><SENT sid="562" pm="."><plain>[19]ToyRPeirisPMGhaghadaKBKarathanasisE. Shaping cancer nanomedicine: The effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond.) 9(1), 121–134 (2014).24354814 </plain></SENT>
</text></ref><ref id="bibr20-58841"><text><SENT sid="563" pm="."><plain>[20]TombáczEIllésEMajzikAHajdúARidegNSzekeresM. Ageing in the inorganic nanoworld: Example of magnetite nanoparticles in aqueous medium. Croat. </plain></SENT>
<SENT sid="564" pm="."><plain>Chem. </plain></SENT>
<SENT sid="565" pm="."><plain>Acta. 80, 503–515 (2007). </plain></SENT>
</text></ref><ref id="bibr21-58841"><text><SENT sid="566" pm="."><plain>[21]KosmulskiM. Chemical Properties of Material Surfaces. CRC Press 2001. </plain></SENT>
</text></ref><ref id="bibr22-58841"><text><SENT sid="567" pm="."><plain>[22]ZhangYYangMPortneyNG Zeta potential: A surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed. </plain></SENT>
<SENT sid="568" pm="."><plain>Microdevices 10(2), 321–328 (2008).18165903 </plain></SENT>
</text></ref><ref id="bibr23-58841"><text><SENT sid="569" pm="."><plain>[23]HunterRJ Colloid Science: Zeta Potential in Colloid Science: Principles and Applications. Acadedmic Press 1981. </plain></SENT>
</text></ref><ref id="bibr24-58841"><text><SENT sid="570" pm="."><plain>[24]BerryCWellsSCharlesS CA Dextran and albumin derivatised iron oxide nanoparticles: Influence on fibroblasts in vitro. Biomaterials 24, 4551–4557 (2003).12950997 </plain></SENT>
</text></ref><ref id="bibr25-58841"><text><SENT sid="571" pm="."><plain>[25]RieglerJLiewAHynesSO Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury. Biomaterials 34(8), 1987–94 (2013).23237516 </plain></SENT>
</text></ref><ref id="bibr26-58841"><text><SENT sid="572" pm="."><plain>[26]RauchJKolchWLaurentSMahmoudiM. Big signals from small particles: Regulation of cell signaling pathways by nanoparticles. Chem. </plain></SENT>
<SENT sid="573" pm="."><plain>Rev. 113, 3391–3406 (2013).23428231 </plain></SENT>
</text></ref><ref id="bibr27-58841"><text><SENT sid="574" pm="."><plain>[27]LuengoYNardecchiaSMoralesMPSerranoMC Different cell responses induced by exposure to maghemite nanoparticles. Nanoscale 5(23), 11428–11437 (2013).23963338 </plain></SENT>
</text></ref><ref id="bibr28-58841"><text><SENT sid="575" pm="."><plain>[28]MahmoudiMQuinlan-PluckFMonopoliMP Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid β protein fibrillation in solution. ACS Chem. </plain></SENT>
<SENT sid="576" pm="."><plain>Neurosci. 4(3), 475–485 (2013).23509983 </plain></SENT>
</text></ref><ref id="bibr29-58841"><text><SENT sid="577" pm="."><plain>[29]JungCW Surface properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsil. Magn. </plain></SENT>
<SENT sid="578" pm="."><plain>Reson. </plain></SENT>
<SENT sid="579" pm="."><plain>Imaging 13(5), 675–691 (1995).8569442 </plain></SENT>
</text></ref><ref id="bibr30-58841"><text><SENT sid="580" pm="."><plain>[30]ZorkoMLangelÜ. Cell-penetrating peptides: Mechanism and kinetics of cargo delivery. Adv. </plain></SENT>
<SENT sid="581" pm="."><plain>Drug Deliv. </plain></SENT>
<SENT sid="582" pm="."><plain>Rev. 57, 529–545 (2005).15722162 </plain></SENT>
</text></ref><ref id="bibr31-58841"><text><SENT sid="583" pm="."><plain>[31]WadiaJSDowdySF Protein transduction technology. Curr. </plain></SENT>
<SENT sid="584" pm="."><plain>Opin. </plain></SENT>
<SENT sid="585" pm="."><plain>Biotechnol. 13, 52–56 (2002).11849958 </plain></SENT>
</text></ref><ref id="bibr32-58841"><text><SENT sid="586" pm="."><plain>[32]ZhaoMKircherMFJosephsonLWeisslederR. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. </plain></SENT>
<SENT sid="587" pm="."><plain>Chem. 13(4), 840–844 (2002).12121140 </plain></SENT>
</text></ref><ref id="bibr33-58841"><text><SENT sid="588" pm="."><plain>[33]MartinALBernasLMRuttBKFosterPJGilliesER Enhanced cell uptake of superparamagnetic iron oxide nanoparticles functionalized with dendritic guanidines. Bioconjug. </plain></SENT>
<SENT sid="589" pm="."><plain>Chem. 19(12), 2375–2384 (2008).19053308 </plain></SENT>
</text></ref><ref id="bibr34-58841"><text><SENT sid="590" pm="."><plain>[34]CavalliSCarbajoDAcostaM Efficient γ-amino-proline-derived cell penetrating peptide–superparamagnetic iron oxide nanoparticle conjugates via aniline-catalyzed oxime chemistry as bimodal imaging nanoagents. Chem. </plain></SENT>
<SENT sid="591" pm="."><plain>Commun. 48, 5322–5324 (2012). </plain></SENT>
</text></ref><ref id="bibr35-58841"><text><SENT sid="592" pm="."><plain>[35]KondoESaitoKTashiroY Tumour lineagehoming cell-penetrating peptides as anticancer molecular delivery systems. Nat. </plain></SENT>
<SENT sid="593" pm="."><plain>Commun. 3(951) (2012). </plain></SENT>
</text></ref><ref id="bibr36-58841"><text><SENT sid="594" pm="."><plain>[36]SvensenNWaltonJGBradleyM. Peptides for cell-selective drug delivery. Trends Pharmacol. </plain></SENT>
<SENT sid="595" pm="."><plain>Sci. 33(4), 186–192 (2012).22424670 </plain></SENT>
</text></ref><ref id="bibr37-58841"><text><SENT sid="596" pm="."><plain>[37]YamadaTMehtaRRLekmineF A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol. </plain></SENT>
<SENT sid="597" pm="."><plain>Cancer Ther. 8(10), 2947–2958 (2009).19808975 </plain></SENT>
</text></ref><ref id="bibr38-58841"><text><SENT sid="598" pm="."><plain>[38]WarsoMARichardsJMMehtaD A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br. </plain></SENT>
<SENT sid="599" pm="."><plain>J. </plain></SENT>
<SENT sid="600" pm="."><plain>Cancer 108(5), 1061–1070 (2013).23449360 </plain></SENT>
</text></ref><ref id="bibr39-58841"><text><SENT sid="601" pm="."><plain>[39]ReichertJMValge-ArcherVE Antibody cancer therapeutics. Nat. </plain></SENT>
<SENT sid="602" pm="."><plain>Rev. </plain></SENT>
<SENT sid="603" pm="."><plain>Drug Discov. 6, 349–356 (2007).17431406 </plain></SENT>
</text></ref><ref id="bibr40-58841"><text><SENT sid="604" pm="."><plain>[40]KangHWJosephsonLPetrovskyAWeisslederRBogdanovAJr. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug. </plain></SENT>
<SENT sid="605" pm="."><plain>Chem. 13(1), 122–127 (2002).11792187 </plain></SENT>
</text></ref><ref id="bibr41-58841"><text><SENT sid="606" pm="."><plain>[41]SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWL Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177–182 (1987).3798106 </plain></SENT>
</text></ref><ref id="bibr42-58841"><text><SENT sid="607" pm="."><plain>[42]HuhYJunYSongH In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J. Am. </plain></SENT>
<SENT sid="609" pm="."><plain>Chem. </plain></SENT>
<SENT sid="610" pm="."><plain>Soc. 127(35), 12387–12391 (2005).16131220 </plain></SENT>
</text></ref><ref id="bibr43-58841"><text><SENT sid="611" pm="."><plain>[43]DilnawazFSinghAMohantyCSahooSK Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31(13), 3694–3706 (2010).20144478 </plain></SENT>
</text></ref><ref id="bibr44-58841"><text><SENT sid="612" pm="."><plain>[44]VigorKLKyrtatosPGMinogueS Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. Biomaterials 31(6), 1307–1315 (2010).19889453 </plain></SENT>
</text></ref><ref id="bibr45-58841"><text><SENT sid="613" pm="."><plain>[45]PirauxHHaiJVerbekeP Transferrin receptor-1 iron-acquisition pathway – Synthesis, kinetics, thermodynamics and rapid cellular internalization of a holotransferrin-maghemite nanoparticle construct. Biochim. </plain></SENT>
<SENT sid="614" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="615" pm="."><plain>Acta – Gen. </plain></SENT>
<SENT sid="616" pm="."><plain>Subj. 1830(8), 4254–4264 (2013). </plain></SENT>
</text></ref><ref id="bibr46-58841"><text><SENT sid="617" pm="."><plain>[46]MontetXMontet-AbouKReynoldsFWeisslederRJosephsonL. Nanoparticle imaging of integrins on tumor cells. Neoplasia 8(3), 214–222 (2006).16611415 </plain></SENT>
</text></ref><ref id="bibr47-58841"><text><SENT sid="618" pm="."><plain>[47]XieJChenKLeeH Ultrasmall c(RGDyK)-coated Fe 3 O 4 nanoparticles and their specific targeting to integrin r v 3-rich tumor cells. J. Am. </plain></SENT>
<SENT sid="620" pm="."><plain>Chem. </plain></SENT>
<SENT sid="621" pm="."><plain>Soc. 130(24), 7542–7543 (2008).18500805 </plain></SENT>
</text></ref><ref id="bibr48-58841"><text><SENT sid="622" pm="."><plain>[48]KizilelSNazliCErgencAcarHY RGDS-functionalized polyethylene glycol hydrogel-coated magnetic iron oxide nanoparticles enhance specific intracellular uptake by HeLa cells. Int. </plain></SENT>
<SENT sid="623" pm="."><plain>J. </plain></SENT>
<SENT sid="624" pm="."><plain>Nanomedicine 7, 1903–1920 (2012).22619531 </plain></SENT>
</text></ref><ref id="bibr49-58841"><text><SENT sid="625" pm="."><plain>[49]LyonsSO'NealJSontheimerH. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 39, 162–173 (2002).12112367 </plain></SENT>
</text></ref><ref id="bibr50-58841"><text><SENT sid="626" pm="."><plain>[50]SunCVeisehOGunnJ In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 4(3), 372–379 (2008).18232053 </plain></SENT>
</text></ref><ref id="bibr51-58841"><text><SENT sid="627" pm="."><plain>[51]DestouchesDEl KhouryDHamma-KourbaliY Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS One 3, e2518 (2008).18560571 </plain></SENT>
</text></ref><ref id="bibr52-58841"><text><SENT sid="628" pm="."><plain>[52]DestouchesDPageNHamma-KourbaliY A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. Cancer Res. 71(9), 3296–3305 (2011).21415166 </plain></SENT>
</text></ref><ref id="bibr53-58841"><text><SENT sid="629" pm="."><plain>[53]ChenTShukoorMIWangR Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging. ACS Nano 5(10), 7866–7873 (2011).21888350 </plain></SENT>
</text></ref><ref id="bibr54-58841"><text><SENT sid="630" pm="."><plain>[54]SturgeJWienkeDEastLJonesGEIsackeCM GPI-anchored uPAR requires Endo180 for rapid directional sensing during chemotaxis. J. Cell Biol. 162(5), 789–794 (2003).12952933 </plain></SENT>
</text></ref><ref id="bibr55-58841"><text><SENT sid="632" pm="."><plain>[55]MorosMHernaezBGaretE Monosaccharides versus PEG-functionalized NPs: Influence in the cellular uptake. ACS Nano 6(2), 1565–1577 (2012).22214244 </plain></SENT>
</text></ref><ref id="bibr56-58841"><text><SENT sid="633" pm="."><plain>[56]ValeroETambaloSMarzolaP Magnetic nanoparticles-templated assembly of protein subunits: A new platform for carbohydrate-based MRI nanoprobes. J. Am. </plain></SENT>
<SENT sid="635" pm="."><plain>Chem. </plain></SENT>
<SENT sid="636" pm="."><plain>Soc. 133(13), 4889–4895 (2011).21384882 </plain></SENT>
</text></ref><ref id="bibr57-58841"><text><SENT sid="637" pm="."><plain>[57]WeitmanSDLarkRHConeyLR Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52(12), 3396–3401 (1992).1596899 </plain></SENT>
</text></ref><ref id="bibr58-58841"><text><SENT sid="638" pm="."><plain>[58]LowPSHenneW aDoorneweerdDD Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. </plain></SENT>
<SENT sid="639" pm="."><plain>Chem. </plain></SENT>
<SENT sid="640" pm="."><plain>Res. 41(1), 120–129 (2008).17655275 </plain></SENT>
</text></ref><ref id="bibr59-58841"><text><SENT sid="641" pm="."><plain>[59]FanCGaoWChenZ Tumor selectivity of stealth multi-functionalized superparamagnetic iron oxide nanoparticles. Int. </plain></SENT>
<SENT sid="642" pm="."><plain>J. </plain></SENT>
<SENT sid="643" pm="."><plain>Pharm. 404(1–2), 180–190 (2011).21087660 </plain></SENT>
</text></ref><ref id="bibr60-58841"><text><SENT sid="644" pm="."><plain>[60]SapsfordKEAlgarWRBertiL Functionalizing nanoparticles with biological molecules: Developing chemistries that facilitate nanotechnology. Chem. </plain></SENT>
<SENT sid="645" pm="."><plain>Rev. 113(3), 1904–2074 (2013).23432378 </plain></SENT>
</text></ref><ref id="bibr61-58841"><text><SENT sid="646" pm="."><plain>[61]AlmeidaJPChenALFosterADrezekR. In vivo biodistribution of nanoparticles. Nanomedicine 6(5), 815–835 (2011).21793674 </plain></SENT>
</text></ref><ref id="bibr62-58841"><text><SENT sid="647" pm="."><plain>[62]HillaireauHCouvreurP. Nanocarriers' entry into the cell: Relevance to drug delivery. Cell. </plain></SENT>
<SENT sid="648" pm="."><plain>Mol. </plain></SENT>
<SENT sid="649" pm="."><plain>Life Sci. 66(17), 2873–2896 (2009).19499185 </plain></SENT>
</text></ref><ref id="bibr63-58841"><text><SENT sid="650" pm="."><plain>[63]NelAXiaTMadlerLLiN. Toxic potential of materials at the nanolevel. Science 311(5761), 622–627 (2006).16456071 </plain></SENT>
</text></ref><ref id="bibr64-58841"><text><SENT sid="651" pm="."><plain>[64]GuptaAKCurtisAS Surface modified superparamagnetic nanoparticles for drug delivery: Interaction studies with human fibroblasts in culture. J Mater. </plain></SENT>
<SENT sid="652" pm="."><plain>Sci Mater. </plain></SENT>
<SENT sid="653" pm="."><plain>Med. 15(4), 493–496 (2004).15332623 </plain></SENT>
</text></ref><ref id="bibr65-58841"><text><SENT sid="654" pm="."><plain>[65]SinghNJenkinsGJSAsadiRDoakSH Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 1 (2010). </plain></SENT>
</text></ref><ref id="bibr66-58841"><text><SENT sid="655" pm="."><plain>[66]MahmoudiMSimchiAImaniMMilaniAS SP An in vitro study of bare and poly(ethylene-glycol)-co-fumarate-coated superparamagnetic iron oxide nanoparticles: A new toxicity identification procedure. Nanotechnology 20(22), 225104 (2009).19433870 </plain></SENT>
</text></ref><ref id="bibr67-58841"><text><SENT sid="656" pm="."><plain>[67]BerryCWellsSCharlesSAitchisonG CA Cell response to dextran-derivatised iron oxide nanoparticles post internalization. Biomaterials 25(23), 5405–5413 (2004).15130725 </plain></SENT>
</text></ref><ref id="bibr68-58841"><text><SENT sid="657" pm="."><plain>[68]WuXTanYMaoHZhangM. Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. Int. </plain></SENT>
<SENT sid="658" pm="."><plain>J. </plain></SENT>
<SENT sid="659" pm="."><plain>Nanomedicine 5, 358–399 (2010). </plain></SENT>
</text></ref><ref id="bibr69-58841"><text><SENT sid="660" pm="."><plain>[69]HuangDMHsiaoJKChenYC The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. Biomaterials 30(22), 3645–3651 (2009).19359036 </plain></SENT>
</text></ref><ref id="bibr70-58841"><text><SENT sid="661" pm="."><plain>[70]BurtonLBerganosRShenBChinFTChenX Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: A PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology 260(1), 182–191 (2011).21502381 </plain></SENT>
</text></ref><ref id="bibr71-58841"><text><SENT sid="662" pm="."><plain>[71]LewinskiNColvinVDrezekR. Cytotoxicity of nanoparticles. Small 4, 26–49 (2008).18165959 </plain></SENT>
</text></ref><ref id="bibr72-58841"><text><SENT sid="663" pm="."><plain>[72]GriffithLGSwartzMA Capturing complex 3D tissue physiology in vitro. Nat, Rev, Mol, Cell Biol. 7(3), 211–224 (2006).16496023 </plain></SENT>
</text></ref><ref id="bibr73-58841"><text><SENT sid="664" pm="."><plain>[73]KimJSYoonTJYuKN Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol. </plain></SENT>
<SENT sid="665" pm="."><plain>Sci. 89(1), 338–347 (2006).16237191 </plain></SENT>
</text></ref><ref id="bibr74-58841"><text><SENT sid="666" pm="."><plain>[74]YuMHuangSYuKJClyneAM Dextran and polymer polyethylene glycol (PEG) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture. Int. </plain></SENT>
<SENT sid="667" pm="."><plain>J. </plain></SENT>
<SENT sid="668" pm="."><plain>Mol. </plain></SENT>
<SENT sid="669" pm="."><plain>Sci. 13(5), 5554–5570 (2012).22754315 </plain></SENT>
</text></ref><ref id="bibr75-58841"><text><SENT sid="670" pm="."><plain>[75]AnzaiYPiccoliCWOutwaterEK Radiology for the group evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study. Radiology 228(3), 777–788 (2003).12954896 </plain></SENT>
</text></ref><ref id="bibr76-58841"><text><SENT sid="671" pm="."><plain>[76]GuptaAKGuptaM. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18), 3995–4021 (2005).15626447 </plain></SENT>
</text></ref><ref id="bibr77-58841"><text><SENT sid="672" pm="."><plain>[77]Clemente-CasaresXSantamariaP. Nanomedicine in autoimmunity. Immunol Lett. 158(1–2), 167–174 (2014).24406504 </plain></SENT>
</text></ref><ref id="bibr78-58841"><text><SENT sid="673" pm="."><plain>[78]RichardsJMShawCLangNN In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: Feasibility and safety in humans. Circ. </plain></SENT>
<SENT sid="674" pm="."><plain>Cardiovasc. </plain></SENT>
<SENT sid="675" pm="."><plain>Imaging 5(4), 509–517 (2012).22787016 </plain></SENT>
</text></ref><ref id="bibr79-58841"><text><SENT sid="676" pm="."><plain>[79]MaccioniFBruniAViscidoA MR imaging in patients with Crohn disease: Value of T2-versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology 238(2), 517–530 (2006).16371574 </plain></SENT>
</text></ref><ref id="bibr80-58841"><text><SENT sid="677" pm="."><plain>[80]D'ArienzoAScaglioneGVicinanzaG Magnetic resonance imaging with ferumoxil, a negative superparamagnetic oral contrast agent, in the evaluation of ulcerative colitis. Am. </plain></SENT>
<SENT sid="678" pm="."><plain>J. </plain></SENT>
<SENT sid="679" pm="."><plain>Gastroenterol. 95(3), 720–724 (2000).10710064 </plain></SENT>
</text></ref><ref id="bibr81-58841"><text><SENT sid="680" pm="."><plain>[81]D'ArienzoAScaglioneGBennatoR The prognostic value, in active ulcerative colitis, of an increased intensity of colonic perivisceral fat signal on magnetic resonance imaging with ferumoxil. Am. </plain></SENT>
<SENT sid="681" pm="."><plain>J. </plain></SENT>
<SENT sid="682" pm="."><plain>Gastroenterol. 96(2), 481–486 (2001).11232694 </plain></SENT>
</text></ref><ref id="bibr82-58841"><text><SENT sid="683" pm="."><plain>[82]GagliaJLGuimaraesARHarisinghaniM Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J. Clin. </plain></SENT>
<SENT sid="685" pm="."><plain>Invest. 121(1), 442–445 (2010).21123946 </plain></SENT>
</text></ref><ref id="bibr83-58841"><text><SENT sid="686" pm="."><plain>[83]VellingaMMVrenkenHHulstHE Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: An exploratory study. J. Magn. </plain></SENT>
<SENT sid="688" pm="."><plain>Reson. </plain></SENT>
<SENT sid="689" pm="."><plain>Imaging. 29, 774–779 (2009).19306366 </plain></SENT>
</text></ref><ref id="bibr84-58841"><text><SENT sid="690" pm="."><plain>[84]TourdiasTRoggeroneSFilippiM Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology 264(1), 225–233 (2012).22723563 </plain></SENT>
</text></ref><ref id="bibr85-58841"><text><SENT sid="691" pm="."><plain>[85]EitelIKubuschKStrohmO Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. Circ. </plain></SENT>
<SENT sid="692" pm="."><plain>Cardiovasc. </plain></SENT>
<SENT sid="693" pm="."><plain>Imaging. 4(4), 354–362.21518773 </plain></SENT>
</text></ref><ref id="bibr86-58841"><text><SENT sid="694" pm="."><plain>[86]PayneARBerryCKellmanP Bright-blood T(2)-weighted MRI has high diagnostic accuracy for myocardial hemorrhage in myocardial infarction: A preclinical validation study in swine. Circ. </plain></SENT>
<SENT sid="695" pm="."><plain>Cardiovasc. </plain></SENT>
<SENT sid="696" pm="."><plain>Imaging 4(6), 738–745 (2011).21930836 </plain></SENT>
</text></ref><ref id="bibr87-58841"><text><SENT sid="697" pm="."><plain>[87]YilmazADenglerMAvan der KuipH Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: A human study using a multi-parametric cardiovascular magnetic resonance imaging approach. Eur. </plain></SENT>
<SENT sid="698" pm="."><plain>Hear. </plain></SENT>
<SENT sid="699" pm="."><plain>J. 34(6), 462–475 (2012). </plain></SENT>
</text></ref><ref id="bibr88-58841"><text><SENT sid="700" pm="."><plain>[88]SigovanMGasperWAlleyHFOwensCDSalonerD. USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 265(2), 584–590 (2012).22875796 </plain></SENT>
</text></ref><ref id="bibr89-58841"><text><SENT sid="701" pm="."><plain>[89]DegnanAJPattersonAJTangTYHowarthSPGillardJH Evaluation of ultrasmall superparamagnetic iron oxide-enhanced MRI of carotid atherosclerosis to assess risk of cerebrovascular and cardiovascular events: Follow-up of the ATHEROMA trial. Cerebrovasc. </plain></SENT>
<SENT sid="702" pm="."><plain>Dis. 34(2), 169–173 (2012).22922841 </plain></SENT>
</text></ref><ref id="bibr90-58841"><text><SENT sid="703" pm="."><plain>[90]FergusonPMFeindelKWSlocombeA Strongly magnetic iron nanoparticles improve the diagnosis of small tumours in the reticuloendothelial system by magnetic resonance imaging. PLoS One 8, e56572 (2013).23437173 </plain></SENT>
</text></ref><ref id="bibr91-58841"><text><SENT sid="704" pm="."><plain>[91]WuLCaoYLiaoCHuangJGaoF. Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: A meta-analysis. Eur. </plain></SENT>
<SENT sid="705" pm="."><plain>J. </plain></SENT>
<SENT sid="706" pm="."><plain>Radiol. 80(2), 582–589 (2010).20047813 </plain></SENT>
</text></ref><ref id="bibr92-58841"><text><SENT sid="707" pm="."><plain>[92]HarisinghaniMGBarentszJHahnPF Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. </plain></SENT>
<SENT sid="709" pm="."><plain>J. </plain></SENT>
<SENT sid="710" pm="."><plain>Med. 348, 2491–2499 (2003).12815134 </plain></SENT>
</text></ref><ref id="bibr93-58841"><text><SENT sid="711" pm="."><plain>[93]HeesakkersRAHovelsAMJagerGJ MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: A prospective multicohort study. Lancet Oncol. 9(9), 850–856 (2008).18708295 </plain></SENT>
</text></ref><ref id="bibr94-58841"><text><SENT sid="712" pm="."><plain>[94]RossRWZietmanALXieW Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin. </plain></SENT>
<SENT sid="713" pm="."><plain>Imaging 33(4), 301–305 (2009).19559353 </plain></SENT>
</text></ref><ref id="bibr95-58841"><text><SENT sid="714" pm="."><plain>[95]TriantafyllouMStuderUEBirkhauserFD Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur. </plain></SENT>
<SENT sid="715" pm="."><plain>J. </plain></SENT>
<SENT sid="716" pm="."><plain>Cancer 49(3), 616–624.23084842 </plain></SENT>
</text></ref><ref id="bibr96-58841"><text><SENT sid="717" pm="."><plain>[96]JohnsonLPinderSEDouekM. Deposition of superparamagnetic iron-oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection. Histopathology 62(3), 481–486 (2013).23278862 </plain></SENT>
</text></ref><ref id="bibr97-58841"><text><SENT sid="718" pm="."><plain>[97]MotomuraKIshitobiMKomoikeY SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer. Ann. </plain></SENT>
<SENT sid="719" pm="."><plain>Surg. </plain></SENT>
<SENT sid="720" pm="."><plain>Oncol. 18(12), 3422–3429 (2011).21607775 </plain></SENT>
</text></ref><ref id="bibr98-58841"><text><SENT sid="721" pm="."><plain>[98]MotomuraKIzumiTTateishiS Correlation between the area of high-signal intensity on SPIO-enhanced MR imaging and the pathologic size of sentinel node metastases in breast cancer patients with positive sentinel nodes. BMC Med. </plain></SENT>
<SENT sid="722" pm="."><plain>Imaging 13(32) (2013). </plain></SENT>
</text></ref><ref id="bibr99-58841"><text><SENT sid="723" pm="."><plain>[99]GuimaraesARTabatabeiSDahlDMcDougalWSWeisslederRHarisinghaniMG Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology 71(4), 708–712 (2008).18295316 </plain></SENT>
</text></ref><ref id="bibr100-58841"><text><SENT sid="724" pm="."><plain>[100]FerreiraLKarpJMNobreLLangerR. New opportunities: The use of nanotechnologies to manipulate and track stem cells. Cell Stem Cell 3(2), 136–146 (2008).18682237 </plain></SENT>
</text></ref><ref id="bibr101-58841"><text><SENT sid="725" pm="."><plain>[101]KarussisDKarageorgiouCVaknin-DembinskyAGowda-KurkalliBGomoriJMKassisIBulteJWPetrouPBen-HurTAbramskyOSlavinS. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch. </plain></SENT>
<SENT sid="726" pm="."><plain>Neurol. 67(10), 1187–1194 (2010).20937945 </plain></SENT>
</text></ref><ref id="bibr102-58841"><text><SENT sid="727" pm="."><plain>[102]FigdorCGde VriesIJLesterhuisWJMeliefCJ Dendritic cell immunotherapy: Mapping the way. Nat. </plain></SENT>
<SENT sid="728" pm="."><plain>Med. 10, 475–480 (2004).15122249 </plain></SENT>
</text></ref><ref id="bibr103-58841"><text><SENT sid="729" pm="."><plain>[103]De VriesIJKrooshoopDJScharenborgNM Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63(1), 12–17 (2003).12517769 </plain></SENT>
</text></ref><ref id="bibr104-58841"><text><SENT sid="730" pm="."><plain>[104]De VriesIJMLesterhuisWJBarentszJO Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. </plain></SENT>
<SENT sid="731" pm="."><plain>Biotechnol. 23(11), 1407–1413 (2005).16258544 </plain></SENT>
</text></ref><ref id="bibr105-58841"><text><SENT sid="732" pm="."><plain>[105]SinghDMcMillanJMLiuXM Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues. Nanomedicine (Lond.) 9(3), 469–485 (2014).24646020 </plain></SENT>
</text></ref><ref id="bibr106-58841"><text><SENT sid="733" pm="."><plain>[106]ProvenzanoRSchillerBRaoMCoyneDBrennerLPereiraBJ Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin. </plain></SENT>
<SENT sid="734" pm="."><plain>J. </plain></SENT>
<SENT sid="735" pm="."><plain>Am. </plain></SENT>
<SENT sid="736" pm="."><plain>Soc. </plain></SENT>
<SENT sid="737" pm="."><plain>Nephrol. 4(2), 386–393 (2009).19176796 </plain></SENT>
</text></ref><ref id="bibr107-58841"><text><SENT sid="738" pm="."><plain>[107]Vadhan-RajSStraussWFordD Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am. </plain></SENT>
<SENT sid="739" pm="."><plain>J. </plain></SENT>
<SENT sid="740" pm="."><plain>Hematol. 89(1), 7–12 (2014).23983177 </plain></SENT>
</text></ref><ref id="bibr108-58841"><text><SENT sid="741" pm="."><plain>[108]HetzelDStraussWBernardKLiZUrbonieneAAllenLF A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am. </plain></SENT>
<SENT sid="742" pm="."><plain>J. </plain></SENT>
<SENT sid="743" pm="."><plain>Hematol. 89(6), 646–650 (2014).24639149 </plain></SENT>
</text></ref><ref id="bibr109-58841"><text><SENT sid="744" pm="."><plain>[109]MacdougallICStraussWEMcLaughlinJLiZDellannaFHertelJ. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin. </plain></SENT>
<SENT sid="745" pm="."><plain>J. </plain></SENT>
<SENT sid="746" pm="."><plain>Am. </plain></SENT>
<SENT sid="747" pm="."><plain>Soc. </plain></SENT>
<SENT sid="748" pm="."><plain>Nephrol. 9(4), 705–712 (2014).24458078 </plain></SENT>
</text></ref><ref id="bibr110-58841"><text><SENT sid="749" pm="."><plain>[110]HassanNCahillJRajasekaranSKoveyK. Ferumoxytol infusion in pediatric patients with gastrointestinal disorders: First case series. Ann. </plain></SENT>
<SENT sid="750" pm="."><plain>Pharmacother. 45(12), e63.22116997 </plain></SENT>
</text></ref><ref id="bibr111-58841"><text><SENT sid="751" pm="."><plain>[111]WankhedeMBourasAKaluzovaMHadjipanayisCG Magnetic nanoparticles: An emerging technology for malignant brain tumor imaging and therapy. Expert Rev. </plain></SENT>
<SENT sid="752" pm="."><plain>Clin. </plain></SENT>
<SENT sid="753" pm="."><plain>Pharmacol. 5(2), 173–186 (2012).22390560 </plain></SENT>
</text></ref><ref id="bibr112-58841"><text><SENT sid="754" pm="."><plain>[112]HildebrandtBWustPAhlersO The cellular and molecular basis of hyperthermia. Crit. </plain></SENT>
<SENT sid="755" pm="."><plain>Rev. </plain></SENT>
<SENT sid="756" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="757" pm="."><plain>Hematol. 43(1), 33–56 (2002).12098606 </plain></SENT>
</text></ref><ref id="bibr113-58841"><text><SENT sid="758" pm="."><plain>[113]WustPHildebrandtBSreenivasaG Hyperthermia in combined treatment of cancer. Lancet Oncol. 3(8), 487–497 (2002).12147435 </plain></SENT>
</text></ref><ref id="bibr114-58841"><text><SENT sid="759" pm="."><plain>[114]JohannsenMGneveckowUTaymoorianK Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial. Int. </plain></SENT>
<SENT sid="760" pm="."><plain>J. </plain></SENT>
<SENT sid="761" pm="."><plain>Hyperth. 23(3), 315–323 (2007). </plain></SENT>
</text></ref><ref id="bibr115-58841"><text><SENT sid="762" pm="."><plain>[115]Maier-HauffKRotheRScholzR Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. J. Neurooncol. 81(1), 53–60 (2007).16773216 </plain></SENT>
</text></ref><ref id="bibr116-58841"><text><SENT sid="764" pm="."><plain>[116]Maier-HauffKUlrichFNestlerD Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103(2), 317–324 (2011).20845061 </plain></SENT>
</text></ref><ref id="bibr117-58841"><text><SENT sid="766" pm="."><plain>[117]MatsumineATakegamiKAsanumaK A novel hyperthermia treatment for bone metastases using magnetic materials. Int. </plain></SENT>
<SENT sid="767" pm="."><plain>J. </plain></SENT>
<SENT sid="768" pm="."><plain>Clin. </plain></SENT>
<SENT sid="769" pm="."><plain>Oncol. 16(2), 101–108 (2011).21373775 </plain></SENT>
</text></ref><ref id="bibr118-58841"><text><SENT sid="770" pm="."><plain>[118]MamiyaH. Recent advances in understanding magnetic nanoparticles in AC magnetic fields and optimal design for targeted hyperthermia. Journal of Nanomaterials vol. </plain></SENT>
<SENT sid="771" pm="."><plain>2013 (2013). </plain></SENT>
</text></ref><ref id="bibr119-58841"><text><SENT sid="772" pm="."><plain>[119]ZhangE.KircherM. </plain></SENT>
<SENT sid="773" pm="."><plain>F.KochM. Dynamic magnetic fields remote-control apoptosis via nanoparticle rotation. ACS Nano 8(4), 3192–3201 (2014).24597847 </plain></SENT>
</text></ref><ref id="bibr120-58841"><text><SENT sid="774" pm="."><plain>[120]RiedingerA.GuardiaP.CurcioA. Subnanometer local temperature probing and remotely controlled drug release based on azo*functionalized iron oxide nanoparticles, Nano Lett. 13(6), 2399–2406 (2013).23659603 </plain></SENT>
</text></ref><ref id="bibr121-58841"><text><SENT sid="775" pm="."><plain>[121]KunisakiJ.SaitoT.YamadaT. A possibility of hyperthermia using MRI equipment. Conf. </plain></SENT>
<SENT sid="776" pm="."><plain>Proc. </plain></SENT>
<SENT sid="777" pm="."><plain>IEEE Eng. </plain></SENT>
<SENT sid="778" pm="."><plain>Med. </plain></SENT>
<SENT sid="779" pm="."><plain>Biol. </plain></SENT>
<SENT sid="780" pm="."><plain>Soc. 1, 6373–6375 (2006).17945962 </plain></SENT>
</text></ref><ref id="bibr122-58841"><text><SENT sid="781" pm="."><plain>[122]Cantillon-MurphyP.WaldL. </plain></SENT>
<SENT sid="782" pm="."><plain>L.ZahnM.AdalsteinssonE. Proposing magnetic nanoparticle hyperthermia in low-field MRI. Concepts in Magnetic Resonance Part A 36A(1), 36–47 (2010). </plain></SENT>
</text></ref><ref id="bibr123-58841"><text><SENT sid="783" pm="."><plain>[123]JilesD. Intzroduction to Magnetism and Magnetic materials. CRC Press. </plain></SENT>
</text></ref><ref id="bibr124-58841"><text><SENT sid="784" pm="."><plain>[124]CoeyJMD Magnetism and Magnetic Materials. Cambridge University Press 2009. </plain></SENT>
</text></ref><ref id="bibr125-58841"><text><SENT sid="785" pm="."><plain>[125]ThanhNT Magnetic Nanoparticles: From Fabrication to Medical and Clinical Applications. CRC Press 2011. </plain></SENT>
</text></ref><ref id="bibr126-58841"><text><SENT sid="786" pm="."><plain>[126]WeisslederRNahrendorfMPittetMJ Imaging macrophages with nanoparticles. Nat. </plain></SENT>
<SENT sid="787" pm="."><plain>Mater. 13(2), 125–138 (2014).24452356 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
